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ABSTRACT 
 
Chronic lymphocytic enteritis (CLE) is a fatal condition in the common marmoset (C. 
jacchus) and is characterized by hypoalbuminemia. Fecal alpha1-proteinase inhibitor (α1-PI) 
concentrations can be used to diagnose enteric protein loss in humans, dogs, and cats. Marmoset 
serum α1-PI was purified using immunoaffinity and ceramic hydroxyapatite chromatography, and 
partial characterization was performed. A radioimmunoassay (RIA) and a sandwich enzyme-
linked immunosorbent assay (ELISA) were developed and analytically validated for the 
measurement of α1-PI concentrations in serum and feces. Reference intervals for α1-PI in serum 
and fecal extracts were established for both assays. Fecal α1-PI concentrations were measured in 
marmosets with CLE. Serum cobalamin and folate concentrations serve as markers of 
gastrointestinal disease. Commercially available chemiluminescence immunoassays for the 
measurement of cobalamin and folate in human serum samples were analytically validated for the 
common marmoset. Serum concentrations of cobalamin and folate were measured in healthy 
marmosets and those with CLE. Mast cells have an important role in gastrointestinal disease. Fecal 
N-methylhistamine (NMH) concentrations, a breakdown product of histamine metabolism, was 
measured using a gas chromatography–mass spectrometry assay. Fecal NMH concentrations were 
measured in healthy marmosets and those with CLE.  
The identity of purified marmoset α1-PI was confirmed by peptide mass fingerprinting, N-
terminal amino acid sequencing (EDPQGDAAQKMDTSHH), and by trypsin, chymotrypsin, and 
elastase inhibitory activity. Both the RIA and the ELISA developed were sensitive, linear, 
accurate, precise, and reproducible for the quantification of α1-PI in serum and fecal extracts. 
However, the ELISA had limited linearity and accuracy for spiking recovery of fecal samples. The 
 iii 
  
RIA was used to measure fecal α1-PI concentrations in 9 marmosets with a necropsy diagnosis of 
CLE. Fecal α1-PI concentrations were not elevated in common marmosets with CLE and were not 
significantly different from healthy marmosets or those with other diseases. Low serum folate and 
cobalamin concentrations were moderately sensitive (>70%) and moderately specific (>70%) for 
CLE in marmosets. Fecal NMH concentrations were elevated in 7 of 8 marmosets with CLE and 
one marmoset with lymphoma and ulcerative enteritis. Increased fecal NMH concentrations and 
decreased serum cobalamin and folate concentrations may serve as a marker for CLE. 
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GI   Gastrointestinal 
GALT   Gut-associated lymphoid tissue 
HCl    Hydrochloric acid 
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IgA    Immunoglobulin A 
IgG   Immunoglobulin G 
IBD   Inflammatory bowel disease 
IFCC   International federation of clinical chemistry 
pI   Isoelectric point 
kDa   Kilo dalton 
LLOD    Lower limit of detection 
Mα1-PI   Marmoset alpha1-proteinase inhibitor 
MALDI-TOF-MS  Matrix-assisted laser desorption/ionization time of flight mass  
   Spectrometry 
 
MMP   Metalloproteinases 
mAU    Milli-absorbance units  
MWCO  Molecular weight cut-off 
NMH   N-methylhistamine 
NEPRC   New England primate research center  
O/E    Observed over expected   
PMF   Peptide mass fingerprint (PMF) 
PLE   Protein losing enteropathy 
RIA   Radioimmunoassay  
RIAB   Radioimmunoassay buffer  
Mr    Relative molecular mass 
SDS–PAGE  Sodium dodecyl sulphate electrophoresis polyacrylamide gel  
electrophoresis 
 
SNPRC  Southwest national primate research center 
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SD    Standard deviation 
SAPNA  Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide 
SELDI-TOF-MS  Surface-enhanced laser desorption/ionization time of flight mass  
   Spectrometry 
 
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end labeling  
tTG   Tissue transglutaminase 
Tris   Tromethamine 
WMS    Wasting marmoset syndrome 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 The common marmoset in biomedical research 
The common marmoset (Callithrix jacchus) is a Brazilian New World monkey that has 
been employed in biomedical research since the early 1960 and 1970’s. However, its popularity in 
biomedical research has increased considerably over the years in North America and Europe.1 
Marmosets are gaining popularity because of their small size (350-450 g), reduced cost for 
maintenance, easy husbandry, easy habituation for routine clinical procedures, and decreased 
susceptibility to certain human zoonotic pathogens. Their shorter lifespan, ranging from 7 to 15 
years, and early sexual maturity at an average age of about 1.5 years, also make them an ideal 
species for biomedical research. They also have a high reproductive efficiency with twin and triplet 
births making the self-perpetuation of a research colony easier.1,90 
Currently, the marmoset is used for research in neuroscience, reproductive biology and 
teratology, infectious diseases, immunology, behavior, toxicology, and drug development and 
safety assessment.90 The recent development of transgenic marmosets with germ line 
transmission136 is further expected to increase their popularity in biomedical research. Marmosets 
are used as animal models for aging, stroke, multiple sclerosis, Parkinson’s disease, Huntington’s 
disease, Alzheimer’s disease, and numerous human viral infections.114 There is also a greater 
regulatory acceptance of toxicological data generated in the common marmoset compared to that 
generated with other species.143 Marmosets are born as naturally occurring hematopoietic chimeras 
due to chorionic fusion during early gestational development, thus an individual marmoset has 
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tissues derived from self and sibling embryonic cell lines,110 making them good models to study T 
and B cell-mediated diseases. 
The popularity of marmosets in research has also increased due to shortage in availability 
of Rhesus macaques for research.56 The common marmoset is also the first New World Non-
Human primate after the chimpanzee, macaque, and orangutan whose complete genome has been 
sequenced.33  
 
1.2 Chronic lymphocytic enteritis in the common marmoset 
1.2.1  Wasting marmoset syndrome /disease, or chronic lymphocytic enteritis  
Inflammatory diseases of the intestinal tract, particularly colitis, has been described in 
marmosets.32,38,158 The first described set of marmosets with the ‘wasting marmoset syndrome’ 
(WMS) were reported at the Jersey Zoo in 1976.75 Marmoset wasting disease / syndrome was 
described as a potentially fatal condition characterized by general debilitation, weakening, and loss 
of mobility with no identifiable etiology.75 The term, WMS was initially used for a condition that 
would be observed in recently weaned marmosets,139 but his since then being expanded to include 
the condition in marmosets of all ages.124 WMS is the popular terminology among zoo and 
laboratory veterinarians as it aids in the description of the affected marmosets, who appear to waste 
away and become clinically debilitated and weak. At the same time, the name wasting disease / 
syndrome maybe misleading as the term "wasting disease" has also been used to describe 
conditions in other species in the animal kingdom that have an infectious origin attributed to prions 
in North American deer 165 or viruses in pigs.4 
Recently, use of the term, inflammatory bowel disease (IBD), or more specifically chronic 
lymphocytic enteritis (CLE) has been advocated.88 The nomenclature IBD/CLE is preferred in 
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marmosets as enteritis is the predominant lesion observed in numerous studies.124,175 Lesions in 
marmosets with WMS are not restricted exclusively to the intestinal tract but also include lesions 
of other organ systems, such as the kidney, liver, pancreas, and the musculoskeletal and 
hematopoietic systems.  
WMS has been reported in a number of marmoset species, but has been predominantly 
observed in the Callithrix jacchus.63 Other species of marmosets such as the white-headed 
marmoset/ Geoffroy's marmoset (Callithrix geoffroyi), cotton-top tamarin (Saguinus oedipus) also 
demonstrate a similar spectrum of clinical signs but different diseases.31,125 
A recent study used the term, bone and gastrointestinal syndrome (BGS) instead of WMS 
or CLE, because in most marmosets both systems are affected simultaneously.11  
Inflammatory bowel disease in the human medical literature, refers to a chronic 
inflammatory condition of the distal small intestine and colon, specifically Crohn’s disease, and 
ulcerative colitis as a result of an inappropriate inflammatory response to intestinal microbes in a 
genetically susceptible individual.2 Extra-intestinal manifestations of IBD are common and 
primarily include the musculoskeletal and dermatological systems.85  In the small animal 
veterinary literature, inflammatory bowel disease collectively refers to chronic enteropathy 
accompanied with both recurrent clinical signs and inflammation of the gastrointestinal tract. This 
may be the result of altered genetics, dysbiosis of the gut microbiota, immune system, 
environment, and/or diet.142 Thus, the use of the term chronic lymphocytic enteritis (CLE) to 
describe the disease process in the common marmoset would be most  appropriate.  
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1.2.2 Epidemiology of CLE in the common marmoset 
CLE is seen in marmosets from zoological gardens and research colonies 63,154 in the United 
Kingdom,32 Germany,124 Brazil,144 France,18 United States of America,154 and Japan.108  
IBD, particularly CLE, has been a consistent finding in several C. jacchus colonies at two 
primate centers, the New England Primate Research Center (NEPRC), Southborough, MA and 
Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio 
(SNPRC). Between 1991 and 2000, about 60.5% of all non-experimental marmosets at the NEPRC 
had some degree of IBD.88 In the same center, IBD was observed in about 16% in marmosets less 
than 5.8 years and in 13% in those aged  >5.8years between January 2004 to June 2009.154 In a 
similar study from 2002-2011 at the SNPRC facility, 44% and 31% of deaths were attributed to 
IBD by looking at the causes of mortality for marmosets under the age of 6 and over the age of 6 
years , respectively.131 A disease prevalence between 4-6% among all age groups was seen at the 
German Primate Center from 1977-2000. At this center, marmosets with CLE were found to be 
between 5-7 years old. 124. Fatality in recently weaned marmosets due to CLE has been reported 
to be about 4-5%.139  
In one study, female marmosets were more frequently affected than makes.124 However, 
no sex-related susceptibility has been reported in other studies.88,139 Low birth weight, ancestry, or 
twinning could also not be associated with CLE in marmosets.139 
 
1.2.3 Etiology and pathogenesis 
To date, no definitive etiology for marmoset CLE has been identified. A variety of possible 
etiologies have been suggested, including intestinal pathogens,  nutritional inadequacy, gluten food 
sensitivity, immune-mediated reaction, stress, pancreatic worms (Trichospirura leptostoma), 
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changes in the gut microbiota, digestive efficiency, level of chimerism, or a combination of several 
or even all of these factors.68,88,130,152 
Marmosets in the wild feed on tree exudates, fruits, leaves, insects, and small vertebrates.52 
Nutritional inadequacy, particularly dietary protein deficiency has been described in the common 
marmoset. Clinical signs were  alleviated by supplementation of milk protein in those marmosets.19 
In recently weaned marmosets, high protein foods in the diet also reduced clinical signs of CLE.139 
Circulating antibodies (IgG class) against cereals, citrus fruit, milk, and egg proteins have been 
reported to be present in marmosets,20 suggesting the possible etiology of dietary sensitivity. Also, 
elevated IgA-antigliadin antibodies were also seen in this study. 
Celiac disease in humans is associated with a wide range of presentations and includes an 
increased immunological responsiveness to dietary prolamins, a class of proteins found in wheat, 
barley, rye etc. Gluten sensitivity has been suspected in marmosets as a cause of CLE.52 Increased 
levels of IgA-gliadin antibodies (IgA-AGA) and of IgA-containing circulating immune complexes 
(IgA-CIC), have been reported in marmosets137 with signs of wasting disease compared to healthy 
marmosets. A French study failed to identify changes in serological markers in marmosets with 
CLE.18 Only one out of the 9 cases of marmoset with CLE had histopathological lesions 
comparable to human celiac disease.18 In a more recent study, serum IgA antibodies directed 
against gliadin (AGA), tissue transglutaminase (tTG), and glycoprotein 2 (AGP2A) were measured 
in marmosets on gluten free diets. The addition of gluten to the diet increased AGA, tTG, and 
AGP2A concentrations in some marmosets, and decreased AGA and AGP2A after removal of 
gluten. When marmosets where on the gluten containing diet, more episodes of diarrhea were 
reported. Improved body weights were observed when marmosets were fed gluten-free diets,84 
however the response was not uniform in all the marmosets in the study.  
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CLE in the common marmoset was presumed to be similar to human celiac disease. When 
marmosets were fed a gluten free (recuperation) diet, they showed weight gain. However, when 
the normal colony diet was resumed, clinical signs did not recur. This is in contrast to humans with 
celiac disease in whom a gluten free diet is a lifetime requirement and even tiny amounts of gluten 
may cause severe clinical signs.88 In one study, nutritional intervention induced reversal of CLE 
in the marmoset.36 Histopathology of human patients with celiac disease is also highly variable 
and can show lesions that are comparable to this in marmosets with CLE.23,113 Definitive diagnosis 
of celiac disease in humans requires clinical signs, serology (presence of antitissue 
transglutaminase antibodies), and/or biopsy. Demonstration of improvement, between initial 
diagnosis when the person is on a gluten containing diet is necessary, and after therapy is necessary 
for confirmation.23,134 A more recent study showed that in zoological gardens, clinical signs 
persisted despite the use of gluten free diets. However, in one study the switch to a hypoallergenic 
diet did result in resolution of clinical signs.27  
Trichospirura leptostoma is a pancreatic nematode in the common marmoset. Marmosets 
become infected through ingestion of common cockroaches, which serve as the intermediate host. 
Clinical signs of infection mimic signs in marmosets with CLE.12,121 However, with modern 
husbandry practices in research colonies exposure to cockroaches is very unlikely.  
Changes  in  the fecal  microbiota have been reported in marmosets with signs of CLE, 
particularly with respect to changes in anaerobic bacteria.86 However, another study was unable to 
discriminate the microbiota between marmosets with intestinal inflammation and those without 
intestinal inflammation.7 A more recent study using 16S rRNA sequencing techniques, identified 
changes in composition of bacterial groups between a specific pathogen free (SPF) barrier primate 
colony and a conventional colony, where no evidence of gastrointestinal disease was reported in 
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the SPF colony.130 Altered bacterial groups included Bifidobacterium and Fusobacterium B, with 
the conventional colony having a comparatively high abundance of Fusobacterium B and a low 
abundance of Bifidobacterium, in contrast, to the SPF colony which had a higher abundance of 
Bifidobacterium and lower abundance of Fusobacterium B. 
Marmosets with CLE showed higher levels of chimerism based on quantitative Y-
chromosome PCR in affected tissues such as the jejunum. This increased level of chimerism was 
attributed to infiltrating chimeric lymphocytes contributing to tissue chimerism.152 However, a loss 
of immune tolerance or an immune mediated mechanism is still possible.  
A recent study suggested that gastrointestinal inflammation, leading to impaired digestive 
efficiency and subsequent malabsorption of critical nutrients, leads to clinical signs of CLE.68,175 
A specific etiology has not been identified, and currently CLE is considered to be 
multifactorial in origin with exogenous and endogenous factors leading to an altered intestinal 
immune system, similar to the mechanisms suspected in humans and dogs. 
 
1.2.4 Clinical signs  
The disease is characterized by diffuse to segmental lymphocytic enteritis. Clinical signs 
reported include weight loss, progressing to emaciation, with loss of about 25–50% of body 
weight.31 A body weight <325 g or a weight loss >0.05% of peak weight per day has been 
associated with CLE.11 Muscle atrophy, progressive muscular weakness, stiff hind limb gait, 
progressing to hind limb paralysis12 have also been reported. Diarrhea may or may not be present 
and when present diarrhea may be transient, or chronic (greater than 2 weeks), with high-
viscosity.108 The hair coat can be in poor condition, and tail alopecia can also be seen.84,87 Juveniles 
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fail to thrive, and there is a generalized weakness in weanlings.139 Anorexia and selective eating 
have also been reported.75,86  
 
1.2.5 Clinical pathology 
The most common finding in marmosets with CLE is macrocytic, normochromic anemia 
and hypoalbuminemia.87 Other findings include elevated liver enzyme activities (i.e., ALP, ALT, 
AST)12 and muscle enzyme activity (CK),139 elevated platelet counts,87 and possible 
leucocytosis.108 Low albumin concentrations have been reported in multiple studies.115,175 An 
albumin concentration <3.5 g/dL followed by a body weight <325 g was able to identify 100% of 
the marmosets affected with concurrent bone and gastrointestinal disease.11 However, in another 
study, serum albumin concentrations failed to differentiate between healthy marmosets and those 
with CLE.108 
 
1.2.6 Diagnosis  
Currently, an ante-mortem diagnosis of CLE in the marmoset is made based on clinical 
signs, a history of weight loss, and a decreased serum albumin concentration.11 Clinical criteria 
also include non-responsiveness to common antibiotic therapy or evidence of relapse after short-
term therapeutic success, and a normal appetite.175 The gold standard for the diagnosis of CLE is 
histopathological confirmation of lymphoplasmacytic enterocolitis.88  
A histopathological classification of enteritis based on severity (i.e., negative, minimal, 
mild, moderate, or severe) has been described. This classification takes into account the 
composition of the inflammatory cells (i.e., mononuclear or polynuclear) in the lamina propria, 
crypt abscesses, GALT hyperplasia, and the extent of ulceration.175 Histopathology findings 
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include marked shortening of villi, hyperplasia of the crypt epithelium, lymphocytic infiltrates 
(i.e., T cells, CD3 CD8-positive lymphocytes) that can expand and replace the lamina propria, 
which can be associated with a complete loss of villus architecture ultimately leading to clinical 
signs.88  
 
1.2.7 Differential diagnosis 
Any disease that leads to progressive weight loss in the common marmoset should be 
differentiated from CLE. Such diseases include neoplastic diseases (i.e., spontaneous malignant T 
cell lymphoma,169 small intestinal adenocarcinoma,100 infectious diseases (i.e., Epstein–Barr-
related herpesvirus,126 Mycobacterium tuberculosis,28 helicobacter infections138), parasitic 
diseases (i.e., Giardia sps.,81 Platynosomum sps144), degenerative diseases (i.e., renal disease,19,64 
pancreatic diseases19), systemic inflammatory diseases (i.e., amyloidosis89), and environmental 
stressors.81 CLE may also be seen concurrently with renal disease or systemic amyloidosis, making 
the diagnosis more challenging. 
 
1.2.8 Markers for CLE 
Newer markers such as fecal calprotectin,108 serum matrix metalloproteinases,171 serum 
IgA antibodies to gliadin, and related proteins 84 have recently been investigated.  
Calprotectin is a major protein in neutrophilic granulocytes and fecal calprotectin assays 
have been used to predict intestinal inflammation in human patients with chronic enteritis. The 
concentration of fecal calprotectin is directly proportional to inflammatory neutrophil migration 
towards the intestinal tract and it is believed to induce secretions of various chemokines and the 
promotion of apoptosis.46,173 Fecal concentrations of calprotectin have been explored in the 
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common marmoset. One study showed no alterations in fecal concentrations of calprotectin in 
marmosets with CLE.11 However, another study showed marked increases in the fecal 
concentrations of calprotectin in marmosets with CLE.108 Both studies included a small number of 
marmosets. However, the latter study examined the expression pattern of calprotectin using 
immunocytochemistry to distinguish between marmosets with CLE and healthy controls.108 
Calprotectin expression was seen in the extravascular space of the colon in marmosets with CLE. 
A terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay for the detection 
of DNA fragmentation generated during apoptosis was also increased in the marmosets with CLE 
in this study.  
Metalloproteinases (MMPs) are a group of proteolytic  enzymes that are involved in the 
remodeling and degradation of extracellular matrix. In humans, the overexpression of 
metalloproteinases and weaker expression of their inhibitors have been implicated in the 
development of IBD.67 In humans, measurement of MMP in serum has been reported to help in 
distinguishing between active and inactive IBD.92 Increased serum MMP9 concentrations have 
been reported in marmosets with clinical signs of CLE,171 and these concentrations have also been 
shown to decrease after therapy with tranexamic acid, which coincides with an improvement in 
body weight, hematocrit, albumin, and other parameters.172  
Changes in serum concentrations of IgA antibodies to gliadin and related proteins as 
described before have also been suggested as markers of CLE.  
C-reactive protein (CRP) is an acute phase reactant that can be measured in serum and can 
be used to detect systemic inflammatory disease, including gastrointestinal (GI) disease, in humans 
and dogs.5,105 CRP has also been shown to be an acute phase protein in the marmoset.135 However, 
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CRP concentrations were not found to be significantly different between marmosets with and 
without CLE.11 
Secretory IgA, a fecal indicator of infectious enterocolitis that has also been used as an 
indirect marker of mucosal immunity was also studied in marmosets with CLE and healthy 
controls and no significant changes were observed between these two groups in that particular 
study.11  
Other non-invasive markers, such as serum anti-saccharomyces cerevisiae antibody 
(ASCA), anti-tissue transglutaminase antibody, perinuclear anti-neutrophil cytoplasmic antibody 
(pANCA), and fecal serotonin used for the diagnosis, classification, or monitoring of 
gastrointestinal disease in human medicine and in some veterinary species were studied in the 
marmoset using commercially available assay kits for humans. However, no cross-reactivity was 
appreciated when using these assays.11  
  
 1.2.9  Treatment  
To date, no proven effective treatment for CLE in the marmoset has been described, as the 
final diagnosis is usually made at necropsy.88 Earlier studies have shown that therapeutic measures 
often only lead to temporary improvement and relapses are common.31,63 
Treatment with corticosteroids115 or tranexamic acid172 has been described. In marmosets 
with a body weight ≤325 g and a serum albumin ≤3.5 g/dl for at least 2 weeks, prednisone at 1 
mg/kg, or adjusted budesonide therapy at a starting dose of 0.5 mg per animal for 8 weeks, 
improved body weight, and serum albumin concentrations. However, no confirmation of CLE 
lesions on histolopatholgy was performed in that study.115 Similar results have not been reported 
from other centers.172 
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Tranexamic acid is a plasmin inhibitor that has hemostatic and anti-inflammatory effects. 
Plasmin is an enzyme in the fibrinolytic cascade, that activates matrix metalloproteinases, (MMP), 
particularly MMP9, which has been reported to be increased in marmosets with CLE. In one study, 
6 marmosets with clinical signs of CLE received tranexamic acid therapy [0.5 ml of a 1% solution 
administered intraperitoneally once daily], amino acid supplementation (3 mL into the saphenous 
vein 3 times each week), iron supplementation (0.1 mL, administered orally daily), and rehydrating 
fluid therapy (5 ml of Ringer’s lactate solution with 0.5 mL of a vitamin formulation injected 
subcutaneously 3 times each week) for 8 weeks, followed by a 4 week follow up period. This 
treatment protocol was associated with an increase in body weight, improved anemia (i.e., 
increased hematocrit), increased serum albumin concentration, decreased MMP9 concentration, 
and resolution of tail alopecia in the 4 week follow up period.172  
However, a curative treatment for CLE in the common marmoset has not been described.  
 
1.3 Protein losing enteropathy 
1.3.1 Pathogenesis 
Mechanisms for enteric protein loss include lymphatic obstruction, mucosal disease with 
erosions or ulcerations, or increased mucosal permeability as a result of cell damage or death.155  
 
1.3.2 Alpha1 proteinase inhibitor  
Alpha1 proteinase inhibitor (α1-PI) is a serum glycoprotein synthesized by the liver 80 that 
is released into the systemic circulation and inhibits a variety of serine proteases, protecting tissues 
from enzymatic damage. Recently, α1-PI  has also been described in modulating immunity, 
inflammation, proteostasis, apoptosis, and possibly cellular senescence.61 Alpha1 proteinase 
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inhibitor has been purified in many species, including humans,116 dogs, cats,44 sheep,102 goats,161 
rabbits,79 mice,101 rats,83 guinea pigs,151 Rhesus monkeys,17 and opossums.30 Across different 
species the structure and function of α1-PI are similar. However, a relative deficiency of α1-PI has 
only been reported in people with certain genetic genotypes.60 Deficiency has also been suspected 
in a single dog.98 Limited cross-reactivity for α1-PI has been shown between species.129 
Alpha1 proteinase inhibitor is found in small concentrations within the lumen of the 
gastrointestinal tract. Alpha1-PI  has a molecular weight that is similar to that of albumin it is 
believed to be lost into the intestinal lumen at a rate comparable to that of albumin loss. 
However, unlike albumin, α1-PI is resistant to enzymatic and bacterial degradation within the 
lumen of the gut, allowing for it to be detected in the feces by an immunoassay.96 Fecal α1-PI 
concentrations may be increased even before hypoalbuminemia is observed,150 making it an 
early marker for protein losing enteropathy (PLE). The use of fecal α1-PI as a marker for 
gastrointestinal protein loss has been described as early as 1977 in humans.37 One consistent 
finding in marmosets with chronic lymphocytic enteritis is hypoalbuminemia, which is 
believed to be the result of enteric protein loss. Thus, α1-PI concentrations in feces might help 
to serve as a surrogate marker of enteric protein loss in this species. Currently, analytically 
and clinically validated assays are available for use in humans,72 dogs,58,96 and cats.26  
Increased fecal concentrations of α1-PI have been reported in dogs with 
gastrointestinal disease, particularly IBD and lymphangiectasia,107 acute hemorrhagic 
diarrhea syndrome,57 parvoviral gastroenteritis,104 tylosin responsive diarrhea,164 and also in 
healthy sled dogs after a race.39 In cats, increased fecal concentrations of α1-PI have been 
reported in patients with severe IBD or confirmed gastrointestinal neoplasia.25 In humans, 
increased fecal concentrations have been reported in a variety of gastrointestinal disorders,149 
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and also has been described as an indicator of Crohn's disease activity.99 A good correlation 
has been reported between the gold standard, 51Cr-albumin excretion and fecal α1-PI in 
humans 123 and dogs.94  
 
1.4 Other non-invasive markers of gastrointestinal health 
1.4.1 Serum cobalamin and serum folate concentrations 
 Cobalamin (i.e., vitamin B12) is a water soluble vitamin that is an essential co-factor for 
methylmalonyl CoA mutase. Intestinal absorption of cobalamin is comprised of a multistep 
mechanism, with absorption occurring at receptors on ileal enterocytes91,150 Cobalamin deficiency 
is reported frequently in dogs and cats with exocrine pancreatic insufficiency, distal small 
intestinal disease, diffuse small intestinal disease involving the distal small intestine, or genetic 
defects in certain dog breeds.47 Exocrine pancreatic insufficiency (EPI) causes 
hypocobalaminemia in dogs as the majority of intrinsic factor in dogs is synthesized by pancreatic 
acinar cells,9,35 which are non-functional in dogs with EPI. Ileal disease is believed to lead to 
damage or decreased expression of cobalamin receptors, ultimately leading to reduced cobalamin 
absorption and deficiency once cobalamin stores in the body have been used up. Intestinal 
dysbiosis can also lead to decreased serum cobalamin concentrations.49 The reported prevalence 
of cobalamin deficiency in dogs and cats with gastrointestinal disease ranges from 6-18.5% in 
dogs5,35 and from 17-61% in cats,128,141 respectively. Furthermore, hypocobalaminemia has been 
associated with a negative outcome in dogs with chronic enteropathy5 or exocrine pancreatic 
insufficiency8, and cobalamin supplementation may have a therapeutic potential.132 To the best of 
our knowledge, no data on cobalamin status in marmosets with CLE have previously been 
reported.  
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 Folate (i.e., vitamin B9) is also a water-soluble B complex vitamin. Dietary folate in the 
form of folate polyglutamate is poorly absorbed in the intestinal tract. However, the enzyme, folate 
deconjugase in the jejunal brush border converts folate polyglutamate into monoglutamines, which 
then get absorbed into the enterocytes of the proximal small intestine utilizing specific carriers. 
Chronic intestinal disease damages folate carriers, reducing their uptake, utilization of body stores 
of folate, and ultimately leading to decreased serum concentrations of folate.146 Increased serum 
concentrations have been reported in dogs with intestinal dysbiosis.49 In addition, chronic 
enteropathy also can lead to decreased serum folate concentrations in dogs and cats.35,128 Changes 
in serum cobalamin and/or folate concentrations can serve as surrogate markers for the presence 
of small intestinal disease,49 especially because dietary deficiency of cobalamin and folate is highly 
improbable and it is believed that even withholding food for several weeks duration does not cause 
serum cobalamin and folate concentrations to become subnormal.146 
 
1.4.2 N-Methylhistamine 
Mast cells have been described in the gastrointestinal mucosa of dogs50 and humans127 and 
have been investigated in patients with chronic enteropathy in dogs6,13 and inflammatory bowel 
disease111 in humans. However, mast cells can be missed during evaluation of sections routinely 
stained with hematoxylin and eosin. Their detection requires either special staining with toluidine 
blue or immunohistochemistry for mast cell tryptase.6,13 Markers for mast cell activation rather 
than their absolute numbers seen on histopathology, have also been suggested as a better method 
to measure their activity. Histamine is primarily stored in mast cells and serves as a marker of mast 
cell degranulation. Rapid metabolism of released histamine leads to the formation of N-
methylhistamine (NMH) and imidazole acetaldehyde.153 Fecal concentrations of NMH were found 
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to be increased in a subset of dogs with chronic enteropathy, suggesting that mast cell- mediated 
inflammation plays a role in this condition.6,13 However, the role of mast cells has not been 
investigated in marmoset CLE. 
 
1.5 Biomarkers 
1.5.1 Characteristics for an ideal biomarker 
Markers for the diagnosis and monitoring of marmoset CLE that have a clinical utility have 
not yet been established as evidenced from the studies mentioned before. Non-invasive early 
markers for disease, using blood, urine, or feces would be ideal as opposed to intestinal biopsies 
which in the marmoset can only be obtained surgically or at necropsy. Ideally, these tests should 
be fast, easy to perform, and also facilitate screening of a large number of animals.  
 
1.5.2 Diagnostic tests: immunoassays 
Immunoassays are based on signal responses generated from an antibody–antigen 
interaction. The response is generated from either an enzymatic, luminescent, or radioisotopic label 
attached to the antigen or antibody, or to a secondary binding reaction. The concentration of the 
unknown analyte is calculated from a standard curve.45 Immunoassays such as radioimmunoassays 
(RIA), enzyme-linked immunosorbent assays (ELISA), and enzyme immunoassays (EIAs) are 
routinely used in diagnoses and have been described since the mid-1900s.53 
Any immunoassay has to be analytically validated before routine use. Analytical validation 
involves determining the linearity, accuracy, precision, reproducibility, sensitivity, robustness, and 
stability of the analyte to ensure that immunoassay is suitable for its intended purpose.160 
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1.6 Hypotheses and research objectives 
 1.6.1 Hypotheses 
The hypotheses of this study are: 
1. Common marmosets with chronic lymphocytic enteritis have protein losing 
enteropathy as evidenced by an increased fecal α1-PI concentration.  
2. Common marmosets with chronic lymphocytic enteritis will have altered serum 
concentrations of cobalamin and folate. 
3. Common marmosets with chronic lymphocytic enteritis will have evidence of mast 
cell degranulation in the gastrointestinal tract.  
 
1.6.2 Research objectives 
The objectives of this study are  
(1) To purify and partially characterize α1-proteinase inhibitor from the serum 
of the common marmoset. 
(2) To develop and analytically validate a radioimmunoassay for the 
measurement of α1-proteinase inhibitor concentrations in serum samples 
and fecal extracts from the common marmoset.  
(3) To develop and analytically validate an enzyme linked immunosorbent 
assay for the measurement of α1-proteinase inhibitor concentrations in 
serum samples and fecal extracts from the common marmoset. 
(4) To evaluate α1-proteinase inhibitor concentrations in fecal extracts from 
healthy marmosets and marmosets with chronic lymphocytic enteritis.  
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(5) To measure serum concentrations of cobalamin and folate in healthy 
marmosets and marmosets with chronic lymphocytic enteritis.  
(6) To measure fecal concentrations of N-methylhistamine in healthy 
marmosets and marmosets with chronic lymphocytic enteritis. 
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CHAPTER II 
PURIFICATION AND PARTIAL CHARACTERIZATION OF α1-PROTEINASE  
INHIBITOR IN THE COMMON MARMOSET (CALLITHRIX JACCHUS)* 
 
2.1 Introduction 
 The common marmoset (Callithrix jacchus) is a Brazilian new world monkey that has been 
employed in biomedical research since the early 1960’s. Its popularity has increased considerably 
over the years in North America and Europe.1 Marmosets are utilized because of their small size, 
reduced cost for maintenance, easy husbandry, rapid reproductive turnover, and decreased 
susceptibility to certain human pathogens.  Currently they are used for research in neuroscience, 
reproductive biology, infectious diseases, behavioral science, drug development, and safety 
assessment, as well as models of aging research.90 Recently, a transgenic marmoset with germ line 
transmission has been developed,136 which holds great potential for further biomedical research. 
Inflammatory diseases of the intestinal tract, particularly colitis, have been described in 
marmosets.32,38,158 Inflammatory bowel disease (IBD), particularly chronic lymphocytic enteritis 
(CLE), has been a consistent finding in C. jacchus colonies as evidenced by necropsy findings at 
two primate centers, the NEPRC and SNPRC. Between 1991 and 2000 approximately 60.5% of 
all marmosets used as controls in various studies had some degree of IBD at necropsy at the 
NEPRC. Also, between January 2004 and June 2009, IBD was observed in about 16% of 
marmosets who were >1year of age at the NEPRC.154 In a similar study at the SNPRC facility 
from 2002 to 2011, IBD was attributed as the cause of death in 44% of marmosets below the age 
*Reprinted with permission from Parambeth JC, Suchodolski JS, Steiner JM, 2015.Purification 
and partial characterization of α1-proteinase inhibitor in the common marmoset (Callithrix 
jacchus). Research in Veterinary Science 2015 99:17-22. Copyright (2015) by Elsevier. 
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of 6 years.131 While no specific etiology has been identified, many etiological factors such as gluten 
sensitivity, dietary protein deficiency, and the pancreatic spirurid nematode (Trichospirura 
leptostoma) have been reported.88 The disease is characterized by diffuse to segmental 
lymphocytic enteritis, and clinically manifests itself by failure to thrive in juveniles, or weight loss 
in adults, with or without diarrhea. A diagnosis is made based on clinical signs, a history of weight 
loss, and clinicopathological findings like a decreased serum albumin concentration. No effective 
treatment exists and a final diagnosis is usually made only at necropsy.88   
 Alpha1-proteinase inhibitor (α1-PI) is a serum glycoprotein synthesized by the liver,80 
released into systemic circulation, and inhibiting a variety of serine proteases that protect various 
tissues from enzymatic damage. Recently, α1-PI has also been described as being of importance in 
modulating immunity, inflammation, proteostasis, apoptosis, and possibly cellular senescence.61 
Alpha1-proteinase inhibitor has been purified from many species including human,116 dog,97 cat,44 
sheep,102 goat,161 rabbit,79 mouse,101 rat,83 guinea pig,151 Rhesus macaque,17 and opossum.30 Across 
species, the protein structure and function remain similar, however, a relative deficiency has been 
reported in people with certain genetic genotypes.21 Deficiency of α1-PI has also been reported in 
a single dog.98 However, there is limited cross-immuno-reactivity for α1-PI between species and 
thus assays for the measurement of α1-PI  are species-specific.129 
 Under physiologic conditions only minimal amounts of alpha1-proteinase inhibitor are 
found within the lumen of the gastrointestinal tract. Having a molecular weight similar to albumin, 
it is believed to be lost into the gastrointestinal tract at a rate comparable to that of albumin. 
However, unlike albumin, α1-PI is resistant to bacterial degradation or the effects of digestive 
enzymes within the lumen of the gut, enabling it's detection in fecal samples by an 
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immunoassays.96 Fecal α1-PI may be increased even before hypoalbuminemia is observed, making 
it an early marker for intestinal protein loss.159 Validated assays for measurement of fecal alpha1-
proteinase inhibitor for detection of intestinal protein loss are available for humans,72 dogs,58,96 
and cats.26  
 Marmoset α1-PI has not yet been purified or characterized. The objective of this study was 
to purify and partially characterize α1-PI from the serum of the common marmoset (Callithrix 
jacchus). The purified marmoset α1-PI will then be utilized for the development of an 
immunoassay as a noninvasive marker of chronic lymphocytic enteritis and protein loss in 
marmosets. 
 
2.2 Materials and methods 
2.2.1 Marmoset serum  
 Surplus serum submitted to the Gastrointestinal Laboratory for routine testing (NEPRC), 
and sera harvested from euthanized common marmosets as part of routine colony management 
procedures (SNPRC) were used. These procedures were approved by the animal care and use 
committee at the respective institution. Serum samples were stored at -80oC and shipped on dry 
ice.  
 
2.2.2 Affinity column chromatography 
 An empty column (XK 16/20, GE Healthcare Life Sciences, Piscataway, NJ) was packed 
with 11.8 ml of alpha1-antitrypsin select resin (alpha1-antitrypsin select media, GE Healthcare 
Biosciences, Piscataway, NJ) as per manufacturer’s instructions. This column was stored in 20% 
ethanol at +4oC until further use. Pooled marmoset serum was diluted in a 1:10 dilution with Buffer 
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A; [20 mM Tris(hydroxymethyl)aminomethane hydrochloride (Sigma-Aldrich, St. Louis, MO), 
50 mM sodium chloride (Sigma-Aldrich, St. Louis, MO), pH 7.4]. After thorough mixing, the 
sample was filtered through a 0.2 µm pore size filter and applied to the column coupled with a 
preparative fast protein liquid chromatography (FPLC) system (ÄKTA, GE Healthcare 
Biosciences, Piscataway, NJ). Before loading the serum sample, the column was equilibrated with 
50 ml of Buffer A at a flow rate of 2 ml/min, and then with 50 ml of Buffer B; [20 mM Tris-HCl, 
2 M magnesium chloride hexahydrate (Sigma-Aldrich, St. Louis, MO), pH 7.4] at 4 ml/min. The 
sample was injected and the absorbance at 280 nm monitored. The peak that resulted from the 
injection was allowed to return to baseline. Subsequently, buffer B was applied at a flow rate of 4 
ml/min. One milliliter fractions were collected during the elution phase and analyzed using sodium 
dodecyl sulphate electrophoresis polyacrylamide gel electrophoresis (SDS–PAGE) with precast 
gels under reducing conditions (NuPAGE® Novex® 10% Bis-Tris mini-gels, Life Technologies, 
Grand Island, NY) and using a known molecular weight standard marker (Mark 12, Life 
Technologies, Grand Island, NY). The affinity column was cleaned using 50 ml of each: 2 M 
sodium chloride (Sigma-Aldrich, St. Louis, MO), 6 M guanidine HCl (Sigma-Aldrich, St. Louis, 
MO), and 10% isopropyl alcohol (Sigma-Aldrich, St. Louis, MO) in succession, and then stored 
in 20% ethanol (Decon Labs, King of Prussia, PA). All the buffers used were prepared in ultrapure 
water with 18.2 MΩ.cm resistivity at +25°C (Milli-Q, EMD Millipore Corporation, Billerica, 
MA), and were filtered (0.2 µm), and degassed before use. 
 
2.2.3 Buffer exchange and concentration 
 Eluted fractions that contained protein of the expected molecular weight of marmoset α1-
PI (approximately 50 kDa) were pooled. Buffer was exchanged to buffer C [10 mM sodium 
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phosphate (Sigma-Aldrich, St. Louis, MO), pH 6.95] using a dialysis cassette (Slide-A-Lyzer 
dialysis cassettes, 10K MWCO, Thermo Fisher Scientific, Rockford, IL) as per manufacturer’s 
recommendations. The dialyzed material was concentrated to a final volume of 4 ml using 
centrifugal filters (Amicon® Ultra 15 ml filter, EMD Millipore Corporation, Billerica, MA) and 
stored at -80oC.  
 
2.2.4 Ceramic hydroxyapatite chromatography (CHT) 
 A 5 ml pre-packed ceramic hydroxyapatite chromatography type II media cartridge (Bio 
ScaleTM Mini CHT Type II, Bio-Rad, Hercules, CA) was used. The CHT column was connected 
to the purification system and prepared for injection after equilibration with 25 ml of buffer C, 
followed by 25 ml of buffer D [400 mM sodium phosphate (Sigma-Aldrich, St. Louis, MO), pH 
6.95]. The concentrated protein was injected onto the CHT column at a flow rate of 1 ml/min and 
the flow-through was collected in 1 ml fractions. These fractions were screened for protein activity 
using the trypsin inhibitory activity assay (see 2.7.1). Fractions that had the highest activity were 
pooled, buffer exchanged as before to phosphate buffered saline pH 7.2 (BupH phosphate buffered 
saline packs, Thermo Fisher Scientific Inc., Rockford, IL), and concentrated to a final protein 
concentration of 1 mg/ml. The concentrated protein was stored at –80°C for further 
characterization.  
 
2.2.5 Gel electrophoresis and purity 
 Protein purity was determined by reducing SDS-PAGE using precast 10% Bis-Tris mini-
gels (NuPAGE® Novex® 10% Bis-Tris mini-gels, Life Technologies, Grand Island, NY) and 
subsequent staining with a ready-to-use colorimetric stain formulated with Coomassie dye R-250 
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(Imperial protein stain, Thermo Fisher Scientific, Rockford, IL) as per manufacturer’s 
recommendation.  
 
2.2.6 Protein concentration  
 Protein concentration was determined using the Bradford protein assay (Thermo Scientific 
Pierce, Rockford, IL).  
 
2.2.7 Proteinase inhibitory activity 
2.2.7.1 Trypsin inhibitory activity  
 Trypsin inhibitory activity was measured using a previously established assay44 and was 
used to monitor the purification process. Briefly, bovine trypsin (Sigma-Aldrich, St. Louis, MO) 
and Nα-benzoyl-DL-arginine-p nitroanilide (BAPNA, Sigma-Aldrich, St. Louis, MO) were used 
as the proteinase and the substrate, respectively. The change in absorbance due to the release of p-
nitroanilide was used to measure trypsin activity in a 96-well microtitre plate. The activity was 
measured over a 15 minute interval at a wavelength of 405 nm on a kinetic plate reader.  
Absorbance of each well was measured every 30 seconds. The maximum rate of change in 
absorbance was automatically calculated by integrating across the 30 different measurement points 
and was used for calculating trypsin activity. For the purpose of this study, one arbitrary unit of 
specific activity was defined as the amount of marmoset α1-PI necessary to reduce the maximum 
rate of change of absorbance of the test wells to 50% of the negative control well. 
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2.2.7.2 Elastase inhibitory activity  
 Elastase inhibitory activity was assayed as described previously.148 Briefly, 
methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide was used as the substrate for human neutrophil 
elastase (SERVA Electrophoresis GmbH, Heidelberg, Germany) in a 96-microwell format. 
Elastase inhibition was determined by the absence of an increase in the absorbance, measured over 
15 minutes at a wavelength of 405 nm in a microwell where marmoset α1-PI was pre-incubated 
with the enzyme.  
 
2.2.7.3 Chymotrypsin inhibitory activity   
 Chymotrypsin inhibitory activity was assayed as described previously.106 Briefly, 
inhibitory activity was demonstrated using 0.35 mM succinyl-Ala-Ala-Pro-Phe-p-nitroanilide 
(SAPNA, Sigma-Aldrich, St. Louis, MO) as substrate with a chymotrypsin solution  of 15 U/ml 
in a microtitre 96 well plate and reading the activity using a plate reader at 405 nm. Similar to 
other enzyme inhibitory activities, when the enzyme was pre-incubated with marmoset α1-PI, the 
lack of increase in the absorbance measured over 15 minutes at a wavelength of 405 nm was used 
to determine chymotrypsin inhibitory activity. 
 
2.2.8 Determination of molecular weight and relative molecular mass 
 Molecular weight was estimated by using 10% Bis Tris polyacrylamide gel electrophoresis 
under reducing conditions, against a standard protein ladder (Mark 12, Life Technologies, Grand 
Island, NY). The molecular weight was estimated using gel analysis software (Quantity One 1-D 
Analysis Software, Bio-Rad Laboratories, Hercules, CA). The relative molecular mass (Mr) was 
estimated using surface-enhanced laser desorption/ionization time of flight mass spectrometry 
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(SELDI-TOF-MS;Protein Chip® SELDI, System, Bio-Rad Laboratories, Hercules, CA) using 6 
ng of purified marmoset α1-PI immobilized onto a nonselective normal phase chromatographic 
array (NP 20 Protein Chip® array, Hercules, CA ).  
 
2.2.9 Isoelectric point 
 The pI (isoelectric point) was estimated using native isoelectric focusing with a linear pH 
gradient from 3 to 10 in a vertical format on a precast polyacrylamide gel (Novex® pH 3-10 IEF 
protein gel, Life Technologies, Grand Island, NY).  
 
2.2.10 Specific absorbance 
 Specific absorbance of marmoset α1-PI was determined by using the absorbance as 
measured by the spectrophotometer (NanoDrop 1000, NanoDrop products, Wilmington, DE) and 
the corresponding protein concentration as determined by a Bradford protein assay.  
 
2.2.11 N-terminal amino acid sequence and tryptic peptide mass fingerprint (PMF) 
 The purified protein was submitted to the Protein Chemistry Laboratory (Department of 
Biochemistry and Biophysics, Texas A&M University, TX) for N-terminal amino acid sequencing 
using automated Edman’s protein sequencing on a Model 492 automated protein sequencer 
(Applied Biosystems, Foster City, CA). This was followed by comparing the sequence against an 
established database. Homology between species was determined using the percentage of 
homologue amino acids of the amino acid sequence portion determined.  
 The purified protein on a gel was submitted to the Protein Chemistry Laboratory at Texas 
A&M University for tryptic mass fingerprinting. Briefly, the gel was subjected to tryptic digestion 
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and the resulting peptides were extracted and the unfractionated mixture was analyzed by Matrix-
assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS). Tandem 
mass spectra were extracted, charge state deconvoluted and deisotoped by Mascot Distiller version 
2.2.1. All MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 
Mascot) and X! Tandem (The GPM, thegpm.org; version CYCLONE (2010.12.01.1)). The 
spectrum modeler, X! Tandem was set up to search a subset of the NCBInr_20110312 database. 
Mascot was set up to search the NCBInr_20110312 database (unknown version, 13366630 entries) 
assuming the digestion with trypsin. Mascot and X! Tandem were searched with a fragment ion 
mass tolerance of 0.80 Da and a parent ion tolerance of 1.5 Da. Oxidation of methionine and 
iodoacetamide derivative of cysteine were specified in Mascot and X! Tandem as variable 
modifications. Scaffold (version Scaffold_3.1.2, Proteome Software Inc., Portland, OR) was used 
to validate MS/MS based peptide and protein identifications. Peptide and protein identifications 
were accepted as per specifications from the Peptide Prophet algorithm74 and Protein Prophet 
algorithm.109  
 
2.2.12 Immunologic cross-reactivity and Western blotting 
 Polyclonal antibodies were raised in a New Zealand white rabbit by inoculation with 200 
µg of purified marmoset α1-PI emulsified in Freund’s complete, and then by repeated injections of 
100 µg of purified marmoset α1-PI in Freund’s incomplete adjuvant by a commercial antibody 
production service (Lampire Biological Laboratories, Pipersville, PA). Specificity of antibodies 
raised were determined by using a Western blot, using marmoset serum, pooled protein fractions 
from the A1AT select affinity column (Alpha1-antitrypsin select medium consists of binding 
ligands made from camelidae-derived single domain antibody fragments, obtained after 
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immunization of lamas with human A1AT protein on an agarose matrix), and purified marmoset 
α1-PI. A 1:5000 dilution of the primary antibody with approximately a titer of 80%, and a 1:50,000 
dilution of secondary antibody (Goat anti-Rabbit IgG, Pierce, Thermo Fisher Scientific Inc., 
Rockford, IL) were used. Cross-reactivity of sera raised against marmoset α1-PI was assayed using 
the radial double immunodiffusion against human, dog, cat, mouse, and rat serum. Various non-
human primate sera from the Houston zoo and the Phoenix zoo were also tested for cross-reactivity 
with marmoset α1-PI. The primate species tested included the Geoffrey’s marmoset,  pied tamarin, 
cotton topped tamarin, golden lion tamarin, ring tailed lemur, black and white ruffled lemur, red 
fronted lemur, mandrill, red capped mangabey, Allen's swamp monkey, De Brazza's monkey, 
Schmidt's monkey, orangutan, Rhesus monkey, pigtail monkey, and the chimpanzee. Marmoset 
serum was used as a positive control and phosphate buffered saline as negative control.  
 
2.3 Results 
2.3.1 Purification of marmoset α1-PI 
Marmoset α1-PI was successfully purified from marmoset serum. Results from an 
exemplary purification are summarized in Table 1. Progression of the purification process was 
monitored by use of SDS-PAGE and the trypsin inhibition assay. Marmoset α1-PI was retained on 
the A1AT select affinity column. The majority of other serum proteins were observed in the flow 
through (Figure. 1). Retained marmoset α1-PI and other proteins were eluted with Buffer B. The 
eluted fractions were visualized on a gel, and fractions with marmoset α1-PI were pooled and 
concentrated. Proteolytic activity could not be measured during this phase because of the 
interference from magnesium ions present in the buffer. Marmoset α1-PI was then concentrated, 
buffer exchanged, and loaded onto the ceramic hydroxyapatite (CHT) column. Marmoset α1-PI 
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did not bind to the column and this step helped to remove other major protein contaminants 
(Figure. 2). The overall yield of the purification protocol was about 11.9%. There was a 19-fold 
increase in the purification. After the final concentration step marmoset α1-PI was visualized as a 
single band on SDS-PAGE after staining (Figure. 3).  
 30 
  
Table 1. Sequential purification of marmoset α1-PI from 2 ml of marmoset serum. Reprinted with permission.120 
Purification stage 
Protein 
content (mg) 
Total inhibitory 
activity (units) 
Specific activity 
(U/mg of 
protein) 
Recovery 
(%) 
Purification 
(fold) 
Serum   111.57 250  2.2   100 1  
Affinity chromatography  2.0 59 29.5  23.6 13  
Ceramic hydroxyapatite 
chromatography 
0.68  30 43.7  11.9 19  
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Figure. 1. Chromatogram for purification with the A1AT select immunoaffinity column. Diluted 
marmoset serum was applied onto the column and the column washed with buffer A. Bound 
marmoset α1-PI was eluted by use of 100% buffer B. Fractions in tubes 17, 18 and 19 on the 
chromatogram (third peak) showed the area corresponding to the band with the highest 
concentration of marmoset α1-proteinase inhibitor. Protein elution was monitored by measurement 
of absorbance (in milli-absorbance units [mAU]) at 280 nm. Reprinted with permission.120 
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Figure. 2. Ceramic hydroxyapatite chromatography of partially purified marmoset α1-PI. Buffer 
C, at a flow rate of 1 ml/min, was used as the mobile phase. Fractions of the second peak showed 
the highest trypsin inhibition of 100% and were pooled and concentrated. Protein elution was 
monitored by absorbance (in milli-absorbance units [mAU]) at 280 nm. Reprinted with permission 
120 
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Figure. 3. Imperial protein stain stained SDS-PAGE of partially purified marmoset α1-PI. The 
molecular weights of a set of molecular mass markers (Mw) are shown in middle of the gel. The 
following material was loaded into the lanes: lane 1: marmoset serum, 3: pure α1-PI after ceramic 
hydroxyapatite chromatography. Reprinted with permission.120 
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2.3.2 Characterization of marmoset α1-PI  
 The estimated molecular mass on a 10% Bis Tris polyacrylamide electrophoresis gel was 
about 54 kDA.  The relative molecular mass (Mr) was estimated 51,677. The pI (isoelectric point) 
of marmoset α1-PI was revealed by 6 bands in close proximity between 4.8 and 5.4. The specific 
absorbance of marmoset α1-PI was 1.6. The N-terminal amino acid sequence of the last 16 amino 
acids were EDPQGDAAQKMDTSHH, using the single letter code.  Homology between the amino 
acid sequences of marmoset α1-PI and other species like human, dog, cat, horse and sheep were 
81%, 50%, 44%, 44%, and 38%, respectively (Figure. 4). This sequence yielded two hits on 
UNIPROTKB (http://www.uniprot.org) for the common marmoset; one was an unidentified 
protein (F7GL69_CALJA) and the other alpha1-antitrypsin (U3FMP8_CALJA) with 100% 
identity. The tryptic peptide mass fingerprint (PMF) and database search of the PMF data showed 
sequence similarity with alpha1-proteinase inhibitor. Immunologic cross-reactivity determined 
using hyperimmune serum raised against marmoset α1-PI was observed only with serum from the 
Geoffrey’s marmoset among all of the species tested.  
2.4 Discussion 
 No cross-reactivity was observed between marmoset samples on human and canine assays 
and purification of marmoset α1-PI was needed to develop a suitable fecal immunoassay. In this 
study, we report the successful purification of α1-PI from marmoset serum using a two-step 
chromatographic procedure. The identity of marmoset α1-PI was confirmed by tryptic peptide mass 
fingerprinting, primary sequence determination of the N-terminus of the first 16 amino acids, and 
by enzyme inhibition assays. 
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Figure. 4. N-terminal amino acid sequences of α1-PI from different species. This table shows the 
N-terminal amino acid sequence of the last 16 amino acid residues of α1-PI in the common 
marmoset, cat, dog, human being, sheep, and horse. Amino acid residues in bold and underlined 
indicate differences in the sequence, with respect to marmoset α1-PI.  
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 The described protocol is quick, reproducible, and has a good yield. Purified marmoset α1-
PI was sufficiently pure as indicated by a single band on SDS-PAGE.  Marmoset α1-PI purification 
has not been reported elsewhere in literature. Serum availability for purification is a major 
limitation in marmosets because of their small body size and thus limited blood volume; hence a 
process with a high yield was necessary for purification. Though a variety of methods have been 
employed in the purification of serum alpha1-proteinase inhibitors from other species, the use of 
immunoaffinity chromatography has only been described for human sera. Alpha1-antitrypsin 
(A1AT) select medium consists of A1AT binding ligands attached to an agarose matrix. A1AT 
binding ligands are made of camelidae-derived single domain antibody fragments, which were 
obtained from lamas after immunization with human A1AT protein. Very recently, using the same 
immunoaffinity media, human alpha1-antitryspin select was purified with a 60% yield in the initial 
step, with an overall yield of 42% for the entire purification protocol.174 Our yield was lower at 
~12%. This difference may be attributable to the difference in affinity of marmoset α1-PI for the 
A1AT select resin. During the purification process, we observed that after repeated usage of the 
A1AT Select column, a thorough multistep cleaning in-place protocol was necessary to maintain 
column performance. Trypsin inhibitor assay was also found to be altered by high magnesium 
concentrations in the elution buffers during the immunoaffinity purification, thus a buffer 
exchange was necessary.   
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The characteristics of marmoset α1-PI are similar to those of α1-PI from other species. The 
pI between 4.8-5.4 is close to that reported in the cat (4.3-4.7),44 rat (4.3-4.8),83 guinea pig (4.5-
4.9),151 rabbit (4.8-5.0),79 human (4.55-4.47),116 dog (4.7-4.9),97 and sheep (4.95).102 Purified 
marmoset α1-PI did retain its ability to inhibit the proteolytic activity of bovine trypsin, 
chymotrypsin, and human elastase. Similar enzyme inhibitory activity has been reported for α1-PI 
purified from sheep.55 The observed molecular mass of marmoset α1-PI is similar to that reported 
for other species [range: 47 – 72 kDa].17,44,97,116,129 The protein identity was confirmed by N-
terminus amino acid sequencing and PMF which are widely accepted methods for protein 
identification.51 A homology of 81.3% was observed between human and marmoset α1-PI. No 
immunological cross reactivity was observed across other species tested, except for the Geoffrey’s 
marmoset. This limited cross-reactivity was expected and has been reported earlier.129    
 In summary, this is the first report of the successful purification and partial characterization 
of marmoset alpha1-proteinase inhibitor. The purified protein showed considerable homology to 
alpha1-proteinase in other species with regard to activity, Mr, and pI. The purification of the protein 
and development of the hyperimmune serum described here would serve as a prelude to the 
development of an immunoassay for the measurement of fecal marmoset alpha1-proteinase 
inhibitor concentrations. 
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CHAPTER III 
DEVELOPMENT AND ANALYTICAL VALIDATION OF A RADIOIMMUNOASSAY FOR 
THE QUANTIFICATION OF ALPHA1-PROTEINASE INHIBITOR IN SERUM AND FECES 
FROM THE COMMON MARMOSET (CALLITHRIX JACCHUS) 
 
3.1 Introduction 
 The common marmoset (Callithrix jacchus) is a New World primate that is used in 
biomedical research.90 The popularity of the marmoset is related to its small size, relatively 
easy maintenance, absence of certain zoonotic diseases, multiple births at each parturition, and 
relatively short life span.1 However, inflammation of the gastrointestinal tract has been 
commonly reported in common marmosets kept in captivity. The disease has been deemed to 
be endemic, with the reported prevalence ranging from 28–60 % in the laboratory setting.88 
Chronic lymphocytic enteritis (CLE) is associated with chronic progressive weight loss in 
adults despite a good appetite, failure to thrive in juveniles. Diarrhea may or may not be 
present. The only consistent clinical pathological abnormalities are a mild anemia and 
hypoproteinemia.11,88 The disease is often terminal with affected marmosets either dying of 
being euthanized. The current gold standard for diagnosis is necropsy.   
 The development of a non-invasive test that may allow early ante-mortem diagnosis would 
facilitate screening and removal of affected marmosets before they are enrolled in research 
trials or breeding programs, thereby reducing the impact of this disease. Given that 
hypoproteinemia, particularly hypoalbuminemia, has been reported consistently in marmosets 
with chronic inflammation of the intestinal tract, we hypothesize this hypoproteinemia may be 
due an intestinal loss of protein as seen in other species with inflammatory bowel disease. The 
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gold standard for detecting gastrointestinal protein loss is the excretion of 51Cr-albumin in 
feces, which is not feasible as a routine diagnostic test given the radiation hazards involved. 
 Alpha1-proteinase inhibitor (α1-PI) is a serum protein produced by the liver that is only lost 
in minimal quantities into the GI tract during health. Given the similar molecular weight to 
albumin, it is lost into the intestinal tract at a similar rate as is albumin. However, unlike 
albumin, it is resistant to degradation by digestive enzymes and bacteria within the intestinal 
lumen. Intact fecal α1-PI can be detected by immunoassays and have been employed to detect 
increased enteric protein loss in humans,22 dogs,96 and cats.26 In dogs with protein losing 
enteropathy, increased fecal α1-PI concentrations are thought to precede hypoalbuminemia. 
Assays are species specific and do not cross react.146 We described the purification and partial 
characterization of  marmoset α1-PI from marmoset serum.120  
 The aims of this study were to develop and analytically validate an RIA for the 
quantification of α1-PI in serum samples and fecal extracts from marmosets and to establish 
reference intervals for serum and fecal α1-PI concentrations in healthy marmosets. 
 
3.2 Materials and methods 
3.2.1 Marmoset serum & fecal samples  
 Serum and fecal samples previously submitted to the Gastrointestinal Laboratory for 
research testing, and serum harvested from common marmosets euthanized as part of routine 
colony management procedures stored at -80oC and shipped on dry ice were used for assay 
development and analytical validation. 
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3.2.2 Animals 
 A total of 30 marmosets from two research colonies of  common marmosets accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care (Southwest National 
Primate Research Center, Texas Biomedical Research Institute, San 307 Antonio, Texas and the 
Barshop Institute for Longevity & Aging Studies University of Texas Health Science Center at 
San Antonio) were used to establish reference intervals for serum and fecal α1-PI concentrations 
in healthy marmosets. These procedures were approved by the animal care and use committee at 
the respective institutions (AUP 1259CJ & AUP 06120X).  
 Paired serum and naturally passed fecal samples were collected from each animal. Since it 
has been demonstrated that fecal α1-PI concentrations can have day-to-day variations in dogs, and 
no data exists for the common marmoset, fecal samples were collected for three consecutive days 
from each animal. Fecal samples were collected as soon after defecation as possible in pre-weighed 
polypropylene tubes, and stored at -80oC until they were shipped on dry ice. 
 
3.2.3 Extraction of fecal samples 
 Fecal samples were thawed and then the extraction was done using phosphate buffered 
saline supplemented with 5% newborn calf serum, 1% Triton X-100, and 0.25 mM thimerosal in 
a 1:5 dilution using approximately 1.0 g wet weight of feces. The fecal samples were homogenized 
by vortexing for 20 minutes, then centrifuged for 20 min at 2,100 x g and 5°C, and then the 
supernatants [fecal extract] were collected using serum filters, and  were stored frozen at –80°C 
until analysis. This extraction is similar to the extraction described for the canine assay.59 
 
 
 41 
  
3.2.4 Purification of marmoset α1-PI 
 Marmoset alpha1-proteinase inhibitor was purified from marmoset serum by affinity 
chromatography, and ceramic hydroxyapatite chromatography as described previously.120  
 
3.2.5 Antibody production 
 Polyclonal antibodies were raised in New Zealand white rabbits using a commercial 
antibody production service (Express-Line PLUS protocol; Lampire Biological Laboratories, 
Pipersville, Pennsylvania, USA). Purified marmoset α1-PI in phosphate buffered saline was used 
as the antigen and antiserum specificity was tested as previously described.120 Antiserum obtained 
after the fourth booster injection was selected for the RIA procedure with a final dilution, of 
1:5,000.  
 
3.2.6 Dilution of serum samples 
 Serum samples were diluted 1:32,000 in radioimmunoassay buffer (RIAB, 0.05 M sodium 
phosphate, with 0.02% (w/v) sodium azide and 0.5% (w/v) bovine serum albumin (pH 7.5)) for 
the RIA.  
 
3.2.7 Dilution of fecal samples 
 Previously stored fecal extracts were thawed and diluted 1:200 in RIAB for the RIA. 
 
3.2.8 Tracer radioiodination 
 The tracer was produced by iodination of pure marmoset α1-PI with 125I, using the 
chloramine T method.62 A stir bar [8 mm × 1.5 mm; VWR Scientific, West Chester, Pennsylvania, 
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USA] was placed in a polypropylene test tube (75 mm × 12 mm; VWR Scientific) and 10 µL of 
0.25 M sodium phosphate buffer [Sigma-Aldrich, St. Louis, MO] was pipetted into it, which was 
then placed over a stir plate. With the use of a Hamilton syringe (VWR Scientific) 10 µL of carrier 
free I125 [NaI, 1.0 mCi at time of production] (Perkin Elmer, Waltham, MA) was dispensed into 
the tube. Then the following solutions were added in succession: 10 µg of the marmoset α1-PI, 10 
µL of the chloramine T solution [2 mg/mL], 100 µL of a sodium metabisulfite solution (0.4 
mg/mL), and 860 µL of a potassium iodide solution (2 mg/mL). All the solutions used were 
dissolved in 0.05 M sodium phosphate (pH, 7.5). The iodinated mα1-PI fraction was separated 
from the free iodide by size-exclusion chromatography on a disposable column equilibrated with 
10% (wt/vol) bovine serum albumin (PD-10; GE Healthcare, Piscataway, New Jersey, USA) 
following the manufacturer’s directions. The RIA buffer (RIAB) was used as the mobile phase, 
and 1-mL fractions were collected. The fraction containing the peak protein concentration was 
used as the tracer. The tracer was adjusted with RIA buffer to approximately 45,000 
counts/minute/100 μL tracer and kept at 4°C until further use. 
 
3.2.9 Radioimmunoassay procedure 
 All polypropylene reaction tubes (VWR Scientific) were set up in a duplicate fashion. The 
tubes were labelled total count (TC), nonspecific binding (NB), reference blank (B0), and 
standards labelled 100, 50, 20, 10, 5, 2, and 1 ng/mL. The tubes were filled accordingly: TC 
received 100 μL tracer only, NB received 100 μL tracer and 200 μL RIAB, B0 received 100 μL 
tracer, 100 μL antibody solution, and 100 μL RIAB. The standards received 100 μL tracer, 100 μL 
antibody solution, and 100 μL standard solution of 100, 50, 20, 10, 5, 2, and 1 ng/mL mα1-PI in 
RIAB, respectively. Unknown samples received 100 μL tracer, 100 μL antibody solution, and 100 
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μL of the unknown sample. Tubes were vortexed and then incubated for 4 hours at room 
temperature. At the end of the incubation period, all, except the tubes labeled TC, received 100 μL 
of a rabbit carrier serum (1 mL normal rabbit serum mixed with 99 mL RIAB) and 1 mL of a 
commercially available precipitation solution (N6; Siemens Healthcare Diagnostics Inc., 
Tarrytown, New York, USA). All tubes except the TC tubes were vortexed and then centrifuged 
at 3,360 x g and 10°C for 30 min. The supernatant of all tubes, were carefully decanted. The tubes 
were visually inspected to ensure that the pellets were present. The tubes were placed in a gamma 
counter (Riastar; Packard Instrument Company, Meriden, Connecticut, USA) and counted for 1 
minute. A standard curve was generated using a log/logit curve fit. Mα1-PI concentrations were 
marked on the x-axis in a logarithmic fashion and values on the y-axis were calculated from y = 
loge((Bstandard/B0)/(1 – (Bstandard/B0)) with B standard being the counts per minute for each standard 
and B0 being the counts per minute for the reference blank. Test samples containing mα1-PI in 
concentrations greater than the working range of the assay were further diluted by a factor of 2 and 
re-assayed. 
 
3.2.10 Radioimmunoassay validation 
 The mα1-PI RIA was analytically validated by determining the lower limit of the assay, the 
linearity, accuracy, precision, and reproducibility by evaluating assay sensitivity, dilutional 
parallelism, spiking recovery, intra-assay variability, and inter-assay variability. Serum and fecal 
samples were selected at random from the available samples and efforts were made to ensure that 
they fell into different areas of the working range of the assay. Serum samples used for validation 
were generated from a pool of several samples because marmosets are significantly smaller than 
companion animals and serum volumes greater that 0.5 mL were not available for most animals. 
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The lower limit of the assay was determined by analyzing 10 duplicates of the B0 tubes and 
calculating the mean and the standard deviation of the raw counts for the zero mα1-PI 
concentration. The mα1-PI concentration that corresponded to the mean count minus three standard 
deviations was estimated on the standard curve and defined as analytic sensitivity (lower limit of 
the working range) of the RIA. The upper limit of the working range was taken as the highest 
standard. Linearity of the assay was determined by use of 8 serum samples in two fold dilutions 
from 1:32,000 to 1:512,000, and 4 fecal samples in two fold dilutions from 1:1 to 1:16. Accuracy 
of the assay was tested by spiking 4 sera and 4 fecal extracts with known concentrations of pure 
mα1-PI (20, 50, and 100 µg/L for serum samples and 20, 50, and 100 µg/g  for fecal extracts). 
Recovery was determined by calculating the ratio of the observed/expected X 100. Intra-assay 
variability or precision of the assay was evaluated by assaying 8 serum samples, and 8 fecal 
extracts 4 times within the same assay, followed by calculating the coefficient of variation: CV % 
= (SD/mean) X 100. Inter-assay variability or reproducibility of the assay was determined by 
analyzing 8 sera and 8 fecal extracts in 3 consecutive assays and calculating inter-assay coefficient 
of variation; CV % = (SD/mean) X 100. To evaluate if there was a position effect within the assay 
(end of-run effect) two samples were tested in the same run by analyzing each sample 24 times in 
the same assay, with 8 duplicates placed in the beginning, middle, and at the end of the same assay. 
Mean mα1-PI concentration calculated from these positions on the assay were compared using a 
Kruskal-Wallis test (rank sum) test. 
 
3.2.11 Reference interval determination 
 The reference interval for serum concentrations of marmoset α1-PI were determined by 
calculating the central 95th percentile of serum concentrations measured in the 30 healthy 
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marmosets from both the colonies. Fecal α1-PI concentrations were measured in the same 30 
marmosets, and the reference interval was established calculating the 95th central percentiles of 
both, the mean and the maximum fecal α1-PI concentrations in the fecal samples from 3 
consecutive days. The coefficient of variation was also calculated between the three separate fecal 
samples collected. None of the marmosets had any clinical signs of wasting or lymphocytic 
enteritis and therefore at the time of collection of serum or feces and were deemed to be healthy.  
  
3.2.12 Statistical analysis 
 Statistical analyses were performed using a statistical software program [Graph Pad prism 
software, GraphPad Software, Inc. La Jolla, CA 92037 USA) and statistical significance was set 
at p < 0.05. 
 
3.3 Results 
 The lower limit of the assay was calculated to be 0.8 µg/L. The upper limit of the working 
range was calculated to be 100.6 µg/L. Eight serum samples in two fold dilutions from 1:32,000 
to 1:512,000 and 4 fecal samples in two fold dilutions from 1:1 to 1:16 were assayed. The observed 
to expected ratios (O/E) for serial dilutions were (minimum-maximum (mean ± SD)) 89.9 – 123.0 
% (106.0 ± 11.5%) for serum, and 90.6 – 132.7% (107.6 ± 19.2%) for fecal extracts [Table 2, 3]. 
The O/E for spiking recovery for 3 different spiking concentrations were (minimum-maximum 
(mean ± SD)) 97.6 – 104.4% (101.3 ± 3%) for serum and 97.5 – 101.4% (99.2 ± 1.8%) for serum 
[Table 4, 5.]. Intra-assay coefficients of variation (CV %) (n=8) were 1.7, 2.8, 2.8, 3.5, 4.6, 4.6, 
5.6, and 10.6% for serum samples and 2.2, 2.3, 2.7, 3.1, 4.0, 4.3, 4.3, and 5.1% for fecal extracts 
(n=8) [Table 6, 7]. Also, inter-assay coefficients of variation (CV %) (n=8) were 1.3, 5.2, 5.6, 6.3, 
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8.0, 8.2, 8.4, and 9.9% for serum samples and were 1.0, 1.1, 2.6, 3.2, 3.3, 3.8, 4.8, and 6.7% for 
fecal extracts (n=8) [Table 8, 9]. No significant differences in mean α1-PI concentrations 
depending on position of samples in the assay were observed (p=0.4128).  
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Table 2. Dilutional parallelism of a RIA for the measurement of serum α1-PI concentrations in 
the common marmoset 
Serum 
Sample 
ID 
 Dilution  
Observed α1-
PI 
Concentration 
(µg/L) 
Expected α1-
PI 
Concentration 
(µg/L) 
O/E %  
Average 
O/E %  
S1 
1:32000 28.7 N/A N/A   
1:64000 16.2 14.3 113.3   
1:128000 7.1 7.2 98.8   
1:256000 4 3.6 111.6   
1:512000 1.4 1.8 76.1 99.9 
S2 
1:32000 31.4 N/A N/A   
1:64000 19.1 15.7 121.5   
1:128000 7.7 7.9 98.6   
1:256000 5.7 3.9 144.9   
1:512000 2.1 2 109.3 118.6 
S3 
1:32000 29 N/A N/A   
1:64000 17.7 14.5 122.4   
1:128000 7.5 7.2 103.7   
1:256000 4.4 3.6 120.4   
1:512000 2.6 1.8 145.5 123 
S4 
1:32000 30.1 N/A N/A   
1:64000 15.2 15.1 101.2   
1:128000 8.7 7.5 116.2   
1:256000 4.7 3.8 125   
1:512000 2.2 1.9 115.4 114.5 
S5 
1:32000 28.2 N/A N/A   
1:64000 17 14.1 120.5   
1:128000 4.6 7.1 65.8   
1:256000 2.5 3.5 71.1   
1:512000 1.8 1.8 102.4 89.9 
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Table 2. Continued  
Serum 
Sample 
ID 
 Dilution  
Observed α1-
PI 
Concentration 
(µg/L) 
Expected α1-
PI 
Concentration 
(µg/L) 
O/E %  
Average 
O/E %  
S6 
1:32000 28.1 N/A N/A   
1:64000 15.2 14 108.3   
1:128000 5.8 7 81.9   
1:256000 3.6 3.5 103.2   
1:512000 2.1 1.8 118.2 102.9 
S7 
1:32000 34.1 N/A N/A   
1:64000 20.3 17 118.8   
1:128000 10 8.5 117.8   
1:256000 3.9 4.3 90.4   
1:512000 1.7 2.1 81.7 102.2 
S8 
1:32000 31.9 N/A N/A   
1:64000 15.4 16 96.8   
1:128000 7.7 8 96.9   
1:256000 3.7 4 93.5   
1:512000 2 2 100.7 97 
O/E — observed/expected 
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Table 3. Dilutional parallelism of a RIA for the measurement of fecal α1-PI concentrations in the 
common marmoset 
Sample Dilution 
Observed α1-
PI 
Concentratio
n (µg/g)  
Expected α1-
PI 
Concentratio
n (µg/g)  
Observe
d/ 
Expecte
d % 
Average 
O/E% 
F1 
  131.2     
94.7 
1:2 61.1 65.6 93.2 
1:4 30.8 32.8 93.8 
1:8 15.7 16.4 95.4 
1:16 7.9 8.2 96.4 
F2 
  166.8     
90.6 
1:2 74.2 83.4 88.9 
1:4 37.8 41.7 90.5 
1:8 17.5 20.9 84.0 
1:16 10.3 10.4 98.8 
F3 
  90.3     
132.7 
1:2 49.1 45.1 108.8 
1:4 27.8 22.6 123.0 
1:8 14.9 11.3 132.3 
1:16 9.4 5.6 166.6 
F4 
  85.0     
112.4 
1:2 45.6 42.5 107.3 
1:4 21.0 21.2 99.1 
1:8 10.8 10.6 101.7 
1:16 7.5 5.3 141.6 
O/E — observed/expected 
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Table 4. Spiking recovery of a RIA for the measurement of serum α1-PI concentrations in the 
common marmoset. 
Sample 
Spiked 
concentration 
(µg) 
Observed α1-
PI 
Concentration 
(µg/g)  
Expected α1-
PI 
Concentration 
(µg/g)  
Observed/ 
Expected % 
Average 
O/E% 
S1 
- 19.7     
102.6 
10 31.7 29.7 106.7 
25 44.6 44.7 99.8 
50 70.5 69.7 101.2 
S2 
- 21.8     
104.4 
10 35.6 31.8 111.9 
25 46.9 46.8 100.0 
50 72.6 71.8 101.1 
S3 
- 23.1     
99.7 
10 32.5 33.1 98.2 
25 48.6 48.1 101.0 
50 73.0 73.1 99.9 
S4 
- 20.5     
97.6 
10 31.0 30.5 101.6 
25 42.3 45.5 93.2 
50 69.0 70.5 98.0 
O/E — observed/expected 
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Table 5. Spiking recovery of a RIA for the measurement of fecal α1-PI concentrations in the 
common marmoset. 
Sample 
Spiked 
concentration 
(µg) 
Observed α1-
PI 
Concentration 
(µg/g)  
Expected α1-
PI 
Concentration 
(µg/g)  
Observed/ 
Expected % 
Average 
O/E% 
F1 
- 39.1     
97.5 
10 48.4 49.1 98.5 
25 65.0 64.1 101.4 
50 82.5 89.1 92.6 
F2 
- 52.1     
101.4 
10 66.8 62.1 107.6 
25 79.4 77.1 102.9 
50 95.7 102.1 93.7 
F3 
- 44.0     
99.9 
10 55.0 54.0 101.8 
25 68.7 69.0 99.5 
50 92.4 94.0 98.3 
F4 
- 24.0     
97.9 
10 35.7 34.0 104.9 
25 49.5 49.0 100.9 
50 65.1 74.0 88.0 
O/E — observed/expected 
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Table 6. Precision of the RIA for serum α1-PI concentrations in the common marmoset (intra-assay validation). 
Serum 
Sample 
Marmoset α1-PI Concentration (µg/g) 
%CV I II III IV Mean 
S1 - 37.2 39.7 3178.3 38.5 4.6 
S2 40.0 37.4 39.7 38.1 38.8 2.8 
S3 32.0 30.2 31.8 34.3 32.1 4.6 
S4 32.6 33.2 34.8 34.6 33.8 2.8 
S5 36.1 33.8 39.0 38.5 36.8 5.6 
S6 32.3 37.9 42.6 41.8 38.6 10.6 
S7 34.1 33.8 32.7 32.9 33.4 1.7 
S8 30.4 31.7 32.8 30.0 31.2 3.5 
CV: coefficient of variation
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Table 7. Precision of the RIA for fecal α1-PI concentration in the common marmoset (intra-assay validation) 
Fecal Sample 
Marmoset α1-PI Concentration (µg/g) 
%CV I II III IV Mean 
F1 25.4 26.5 26.9 25.7 26.2 2.3 
F2 58.1 59.6 57.3 55.3 57.6 2.7 
F3 40.7 41.9 43.5 44.0 42.5 3.1 
F4 25.3 25.2 26.2 28.0 26.2 4.3 
F5 51.6 50.5 48.9 55.0 51.5 4.3 
F6 31.3 30.1 29.9 29.6 30.2 2.2 
F7 12.1 11.4 12.9 12.9 12.3 5.1 
F8 17.0 16.2 18.2 17.0 17.1 4.0 
CV: coefficient of variation 
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Table 8. Reproducibility of the RIA for serum α1-PI concentrations in the common marmoset 
(inter-assay validation). 
Serum 
Samples 
Marmoset α1-PI Concentration (µg/g) 
% CV I II III Mean 
S1 40.1 38.5 42.9 40.5 5.6 
S2 39.8 40.3 47.3 42.5 9.9 
S3 41.5 41.2 46.0 42.9 6.3 
S4 42.8 40.0 44.3 42.3 5.2 
S5 40.6 41.3 40.3 40.7 1.3 
S6 37.2 34.0 39.9 37.0 8.0 
S7 36.7 35.9 41.7 38.1 8.2 
S8 37.7 33.5 39.6 36.9 8.4 
CV: coefficient of variation 
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Table 9. Reproducibility of the RIA for fecal α1-PI concentrations in the common marmoset 
(inter-assay validation). 
Fecal 
Samples 
Marmoset α1-PI Concentration (µg/g) 
% CV I II III Mean 
F1 60.93 60.14 61.29 60.79 0.97 
F2 59.02 59.73 62.06 60.27 2.64 
F3 73.85 77.42 78.57 76.61 3.21 
F4 67.14 76.26 74.50 72.63 6.66 
F5 39.98 42.83 42.59 41.80 3.79 
F6 93.12 102.35 96.80 97.42 4.77 
F7 84.19 89.94 87.20 87.11 3.30 
F8 74.63 73.16 73.37 73.72 1.08 
CV: coefficient of variation 
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 A reference interval for serum and fecal α1-proteinase inhibitor concentrations (three day 
mean, three day maximum) in feces was calculated using the central 95th percentile using serum 
and fecal samples from healthy control marmosets [Table 10]. The median coefficient of variation 
for fecal α1-proteinase inhibitor concentrations between the three-day fecal samples was 21.4% 
(range: 2.9 – 74.3%). 
 
3.4 Discussion 
 An RIA for the measurement of α1-PI in serum samples and fecal extracts from marmosets 
was successfully developed. The analytical sensitivity of the assay was 0.8 µg/L. This value is 
adequate, considering the reference interval of 1,047 - 1,484 mg/L in serum and 32 - 124 µg/g in 
feces. The O/E values for the dilutional parallelism ranged from 89.9 – 123.0%, 90.6 – 132.7% 
and spiking recovery were 97.6 – 104.4%, 97.5 – 101.4% for serum and feces, respectively. These 
values indicate that the assay is linear and accurate and is close to what has been reported to be 
acceptable of a range of 80-120%.157,160 Two samples, one serum sample with an O/E of 123.0% 
and one fecal sample with an O/E of 132.7% were outside the “acceptable” limits.  
 The coefficients of variability were relatively low for both intra- and inter-assay variability 
the maximum being 10.6%, indicating that the assay is precise and reproducible, and is well within 
the acceptable ranges of <15%.157,160 No effect of position of samples on the run was detected in 
the assay.  
 The reference interval for serum marmoset α1-PI values are comparable with the reference 
intervals reported for canine, feline, and human α1-PI in plasma/serum which are 732-1,802 
mg/L,59 250-600 mg/L,44 and  900-1,200 mg/L,93 respectively.  
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Table 10.  Concentrations of serum and fecal α1-PI in healthy marmosets (n=30) 
  
Concentration of marmoset α1 - PI 
Serum 
concentration  
(mg/L) 
Three day mean 
fecal 
concentration 
(µg/g) 
Three day 
maximum fecal 
concentration (µg/g) 
Reference 
interval  1046 - 1484 32 -124 39 -159 
Median ± SD 1225 ± 130  64 ± 27 78 ± 36 
Range  983 – 1516  31-134 38-190 
 
  
 58 
  
 However, the fecal α1-PI concentrations in healthy cats ranged from 0.04 (i.e., 
undetectable) to 1.72 μg/g (median: 0.51 μg/g). In adult dogs, fecal α1-PI concentrations ranged 
from <2.2 to 26.8 µg/g (median: 4.7 µg/g), whereas in the 30 marmosets in this study the 
concentrations ranged from 30.8-134.0 µg/g (median: 63.5 µg/g). Most human fecal α1-PI assays 
are performed on dried / lyophilized feces. In one study using wet weight of feces, in healthy 
human individuals fecal α1-PI concentrations measure using an ELISA ranged from 1-964 µg/g 
and a concentration of <545 µg/g was considered normal.22 Possible explanations for this finding 
are subclinical disease in some of the marmosets in this study or possibly that marmosets lose more 
α1-PI into their gastrointestinal tract than carnivores. 
 A relatively high coefficient of variation for fecal α1-proteinase inhibitor concentrations 
between the three-day fecal samples were seen in the marmosets (median 21.4%, Range 2.9 – 
74.3%). The reason for this is unknown, however a similarly high CV has also been reported for 
dogs (median: 29.2%, range 0.0% to 102.0%).58 
 As serum and fecal samples were not readily available, stability of samples at different 
storage conditions were not studied. Sample collection and storage conditions used in dogs 58,107 
and cats 25 were presumed to be appropriate. As the samples were collected, stored, extracted, and 
assayed around the same time from the two marmoset colonies, we do not expect this to affect our 
reference interval, however, changes in serum concentrations have been reported in dogs where 
samples were stored over a period of one year.59 
 A limited number of samples were available to establish the serum and fecal reference 
intervals for mα1-PI. Given the small number of animals in the study, no attempts were made to 
make age specific reference intervals, which  may have been more appropriate as younger dogs 
are reported to have higher concentrations of fecal α1-PI.58 Another limitation of this study was 
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that the animals that were used to establish the reference interval were presumed to be healthy 
based on absence of clinical signs, however, given how little is known about the disease, 
subclinical chronic lymphocytic enteritis cannot be ruled out as gastrointestinal biopsies were not 
available. 
 In conclusion, the RIA for the measurement of serum and fecal α1-PI concentrations in the 
common marmoset described here is sensitive, linear, accurate, precise, and reproducible. Further 
studies are needed to determine the utility of this test for diagnosing gastrointestinal disease, 
particularly CLE in the marmoset. 
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CHAPTER IV 
DEVELOPMENT AND ANALYTIC VALIDATION OF A SANDWICH ELISA FOR THE 
MEASUREMENT OF ALPHA1-PROTEINASE INHIBITOR CONCENTRATIONS IN 
SERUM AND FECES FROM THE COMMON MARMOSET (CALLITHRIX JACCHUS)*** 
 
4.1 Introduction 
 The common marmoset (Callithrix jacchus) is a New World primate that is used in 
biomedical research.90 Marmosets are an attractive species for biomedical research because of their 
small size, ease and lower cost of maintenance, ability to be multiparous, lack of susceptibility to 
certain zoonotic diseases, and relatively short life span when compared to other primates.1 
However, gastrointestinal tract inflammation is commonly seen in the common marmosets 
colonies with the prevalence being as high as 60 % in the laboratory setting.88 The etiology of this 
disease remains unknown. Clinical signs may include diarrhea, chronic progressive weight loss in 
adults despite a good appetite, and failure to thrive in juveniles, with anemia and hypoproteinemia. 
The disease is now believed to be a variant of inflammatory bowel disease, particularly when there 
is lymphocytic inflammation. The disease is currently known as chronic lymphocytic enteritis 
(CLE), however previous names included marmoset wasting syndrome88 and bone and 
gastrointestinal disease of marmosets.11 The disease leads to death, and diagnosis is currently made 
at necropsy.  
 Hypoproteinemia associated with this condition is presumed due to intestinal loss of 
protein. Thus, detection of enteric protein loss could facilitate screening and removal of affected  
***Submitted to the American Journal of Veterinary Research (AJVR): Parambeth, JC, Lidbury 
J, Suchodolski J, Steiner J. Development and analytic validation of a sandwich ELISA for the 
measurement of alpha1-proteinase inhibitor concentrations in serum and feces from the common 
marmoset (Callithrix jacchus). 
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marmosets thereby reducing the negative impact of this disease on research utilizing marmosets. 
Excretion of 51Cr-albumin in feces is the test of choice for detecting enteric protein loss, but this 
modality is only available at a few institutions as it is associated with radiation hazards.97 Alpha1-
proteinase inhibitor (α1-PI) is a serum protein that is lost into the intestinal tract at a similar rate to 
albumin because it has a similar molecular weight. As it is resistant to degradation by digestive 
and bacterial enzymes within the intestinal lumen, fecal α1-PI can be detected by immunoassays 
and has been employed to detect enteric protein loss in humans, dogs, and cats.15,25,26,58,96 Recently, 
we described the purification and partial characterization of marmoset α1-PI from marmoset serum. 
The aims of this study were to develop and analytically validate an enzyme-linked immunosorbent 
assay (ELISA) for the measurement of α1-PI concentrations in serum samples and fecal extracts 
from marmosets and to establish reference intervals for serum and fecal α1-PI concentrations in 
healthy marmosets. 
 
4.2 Materials and Methods 
4.2.1 Purification of α1-PI from marmoset serum 
 Marmoset α1-PI was purified from pooled marmoset serum using immunoaffinity 
chromatography and ceramic hydroxyapatite chromatography as previously described.120  
 
4.2.2 Production and purification of marmoset α1-PI antiserum  
 Polyclonal antibodies were raised in a New Zealand white rabbit by inoculation of purified 
marmoset α1-PI emulsified in Freund's complete and Freund's incomplete adjuvant by a 
commercial antibody production service, and the specificity of antibodies were evaluated by 
Western blot analysis, as previously described. Rabbit anti-marmoset α1-PI antibodies were 
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purified by affinity chromatography using a chromatography column (HiTrap NHS-activated HP 
chromatography column; GE Healthcare, Uppsala, Sweden) as per the manufacturer’s instructions. 
The antiserum was applied to this column after lipoprotein precipitation, and buffer exchange to 
75 mM Tris/HCl, 150 mM NaCl, pH 8.0, using a disposable gel filtration column (Disposable PD-
10 desalting column; GE Healthcare). Purified antibodies were buffer exchanged to phosphate-
buffered saline, pH 7.2, concentrated to approximately 1 mg/mL, and stored at −80°C.  
 One aliquot of the purified antibodies was dialyzed with 200 mM carbonate-bicarbonate, 
at pH 9.4, and was coupled with horseradish peroxidase using a commercially available kit (cEZ-
Link Plus Activated peroxidase; Thermo Scientific, Rock- ford, IL, USA) as per the 
manufacturer’s instructions. The conjugate was purified after dialysis against 25 mM Tris/HCl, 
150 mM NaCl, at pH 8.0 using a commercially available purification kit with nickel-chelated 
agarose (Pierce Conjugate purification kit; Thermo Scientific).  
 The purification was followed by another buffer exchange with 100 mM sodium phosphate, 
150 mM NaCl, at pH 7.2. The resultant antibody solution was mixed with 2 parts of a commercial 
conjugate stabilizer solution (SuperFreeze Conjugate stabilizer; Thermo Scientific) as per 
manufacturer’s recommendations and stored at -20oC. 
 
4.2.3 Marmoset serum & fecal samples  
 Serum and fecal samples submitted to the Gastrointestinal Laboratory at Texas A&M 
University for research testing, and sera harvested from common marmosets that were euthanized 
as part of routine colony management procedures, that had been stored at -80oC and shipped on 
dry ice, were used for assay development and validation. Paired serum and naturally passed fecal 
samples were collected from a total of 30 marmosets from two research colonies of the common 
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marmoset (Southwest National Primate Research Center, Texas Biomedical Research Institute, 
San Antonio, Texas and the Barshop Institute for Longevity & Aging Studies University of Texas 
Health Science Center at San Antonio) and were used to establish reference intervals for 
concentrations of serum and fecal α1-PI concentrations in healthy marmosets. Collection of 
samples was approved by the institutions' AUP protocols 1259CJ and 06120X, respectively. Paired 
fecal and serum samples were obtained to ensure that α1-PI deficiency does not occur in individual 
common marmosets as has been described for humans.78 Samples from 3 consecutive days were 
used because fecal α1-PI concentrations in other species have been reported to show considerable 
day-to-day variations.147 Fecal samples were collected into pre-weighed polypropylene tubes 
(gFecal collection tube (101 X 16.5 mm; including spatula), Sarstedt AG & Co, Nümbrecht, 
Germany) as soon as possible after voiding and were stored at -80oC until they were shipped on 
dry ice. 
 
4.2.4 Extraction of fecal samples 
 Fecal samples were thawed to room temperature before extraction. They were extracted 
using phosphate buffered saline supplemented with 5% newborn calf serum, 1% Triton X-100, 
and 0.25 mM thimerosal in a 1:5 dilution, using approximately 1.0 g wet weight of feces. The 
samples were then vortexed for 20 minutes and then centrifuged for 20 min at 2,100 × g and 5°C. 
The supernatants (fecal extracts) were collected using serum filters (Fisherbrand serum filter 
system (IB model), Fisher Scientific Inc, Pittsburgh, PA), and were stored frozen at –80°C until 
further analysis. 
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4.2.5 Preparation of serum samples and fecal extracts 
 Serum samples were diluted 1:64,000 in 0.05 M sodium phosphate, with 0.02% sodium 
azide and 0.5% bovine serum albumin (pH 7.5). Previously stored fecal extracts were thawed and 
diluted in 0.05 M sodium phosphate, with 0.02% sodium azide and 0.5% bovine serum albumin 
(pH 7.5), in order to reach a final dilution of 1:200. 
 
4.2.6 Preparation of standards 
 A 1 mg/ml solution of purified marmoset α1-PI was diluted to concentrations of 100, 50, 
20, 10, 5, 2, and 1 μg/L, using 0.05 M sodium phosphate, with 0.02% sodium azide and 0.5% 
bovine serum albumin (pH 7.5). 
 
4.2.7 Enzyme-linked immunosorbent assay procedure 
 The following procedures were carried out at 37°C. Each well of a ninety-six-well, 
enhanced binding ELISA plate (MaxiSorp Nunc-Immuno Plates, Thermo Scientific) was 
incubated with 100 ng of affinity purified anti-marmoset α1-PI antibodies diluted in 100 μL of 200 
mM carbonate-bicarbonate, pH 9.4 and incubated for 1 hr at 37°C. Three washes with 200 µL of 
25 mM Tris/HCl, 150 mM NaCl, 0.05% polyethylene glycol sorbitan monolaurate (TWEEN-20, 
Sigma–Aldrich, Inc., St. Louis, Missouri), pH 8.0 [wash buffer] were performed for each well. 
Next, 200 µL of 25 mM Tris/HCl, 150 mM NaCl, 0.05% polyethylene glycol sorbitan 
monolaurate, 10% bovine serum albumin, pH 8.0 was used for blocking the nonspecific binding 
sites [blocking buffer]. Plates were incubated again for 1 hr at 37°C, followed by 3 washes with 
wash buffer. Coated plates were stored at 4°C for up to 2 weeks. 
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 All reagents and samples were thawed. A total of 100 μL of seven standard solutions, blank, 
and diluted test samples of serum or fecal extracts were applied to each plate in duplicate fashion 
and incubated for one hour at 37°C. For the blank, an equal volume of 25 mM Tris/HCl, 150 mM 
NaCl, 0.05% polyethylene glycol sorbitan monolaurate, 0.5% bovine serum albumin, pH 8.0 
[assay buffer] was used. Three washes were performed with the wash buffer. The plates were then 
incubated with the HRP-conjugated antibody diluted in assay buffer (50 ng/well) for another hour 
at 37°C. The plates were then once again washed 3 times with the wash buffer. The plate was then 
developed with a 3,3′,5,5′-tetramethyl benzidine (1-Step Ultra TMB-ELISA, Thermo Scientific) 
substrate. After a 5-min incubation, the reaction was stopped by adding 4 M acetic acid 0.5 M 
sulfuric acid [stopping buffer]. The microtiter plate was then read at 450 nm using an automated 
plate reader (Synergy 2 Alpha Microplate Reader; BioTek, Winooski, VT, USA). A commercial 
software package (Gen5 Data Analysis Software v1.05; BioTek) was used to calculate a 5-
parameter logistic curve fit (F(x) = D+(A-D)/((1+(x/C)^B)^E)], which was used to determine α1-
PI concentrations in the test samples.  
 During the initial developmental phase, several parameters of the assay were optimized for 
better performance including titration of the primary and secondary antibodies.  
 
4.2.8 Assay validation 
 The ELISA was validated by determining the lower limit of detection (LLOD), dilutional 
parallelism, spiking recovery, intra-assay variability, and interassay variability. The validation 
procedures were performed separately for serum samples and fecal extracts. The lower detection 
limit of the assay was determined by loading 10 sets of blank controls as unknown samples and 
calculating the mean concentration plus 3 standard deviations for 20 replicates. Four serum 
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samples and four fecal extracts were used to determine dilutional parallelism. Two-fold dilution 
of serum samples from 1:64,000 to 512,000 and a two-fold dilution of fecal samples from 1,000 
to 8,000 were used and the percentage of standard antigen recovery ([observed value 
(ng/g)/expected value (ng/g)] × 100) was calculated in each case. Spiking recovery was determined 
by adding 20, 50, and 100 µg/L of pure marmoset α1-PI to four serum samples and four fecal 
extracts. The percentage of standard antigen recovery ([observed value (ng/g)/expected value 
(ng/g)] × 100) was calculated in each case. Intra-assay variability was determined by evaluating 4 
serum samples and 4 fecal extracts multiple times within the same assay run. The intra-assay 
coefficient of variation (% CV) for each sample (%CV = [SD/mean] × 100) was calculated. Inter-
assay variability was determined by evaluating 4 serum samples and 4 fecal extracts within 
multiple consecutive assay runs. The inter-assay coefficient of variation (%CV) for each sample 
(%CV = [SD/mean] × 100) was calculated.  
 
4.2.9 Position effect 
 Four serum samples and 4 fecal extracts were randomized to 32 positions in duplicates on 
an ELISA plate using an online software (https://www.random.org/lists/). Concentrations were 
compared for the samples using coefficient of variation (%CV) for each sample (%CV = 
[SD/mean] × 100). A Kruskal–Wallis test by ranks was used to compare concentrations from these 
4 positions for each sample. Commercially available software (GraphPad Prism v5.0, GraphPad 
Software, San Diego, CA, USA) was used for the statistical analysis and significance was set at 
p<0.05. 
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4.2.10 Reference interval 
 A reference interval for serum and fecal α1-proteinase inhibitor concentrations (three-day 
mean and three-day maximum) was calculated using the central 95th percentile using serum 
samples and fecal extracts from healthy marmosets with no signs of chronic lymphocytic enteritis. 
Additionally, the mean coefficient of variation for the three fecal samples was calculated for this 
group of marmosets. 
 
4.3 Results 
 Standard curves for the marmoset α1-PI ELISA were reproducible (Figure 5). The lower 
detection limit of the assay was 0.006 μg/L.  
 Observed to expected ratios for serial dilutions for dilutional parallelism were for 4 serum 
samples were (minimum – maximum, mean ± SD): 112.2% – 123.0%, 117.1 ± 5.6% and were 
82.6 – 130.2%, 106.1 ± 19.7% for 4 fecal extracts (Table 11, 12).   
 Observed to expected ratios for spiking recovery for 4 serum samples were (minimum – 
maximum, mean ± SD): 86.8 – 115.8%, 102.9 ± 12.1% and  were 83.0 – 125.1%, 97.9 ± 19% for 
4 fecal extracts (Table 13, 14).   
 Intra-assay variability coefficients of variation (CV %) for 4 serum samples were were 2.4, 
2.4, 2.6, and 4.1% and were 2.6, 5.5, 6.6, and 6.8% for 4 fecal extracts (Table 15, 16). 
 Inter-assay variability coefficients of variation (CV %) for 4 serum samples were 1.7, 3.1, 
3.1, and 6.3% and were 5.1, 8.1, 10.4, and 13.8% for 4 fecal extracts (Table 17,18). 
 No significant position effect was appreciated on the ELISA plate (p=0.9635). The median 
%CV between the positions was 3.5% (minimum to maximum; 2.3% to 6.8%).  
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 A reference interval for serum and fecal α1-proteinase inhibitor concentrations (three-day-
mean and three-day-maximum) was calculated using the central 95th percentile for serum samples 
and fecal extracts from healthy control marmosets The reference interval for serum concentrations 
was  1,254 -1,813 mg/L, 11.5-42.2 µg/g for the three day mean fecal concentration, and 13.2 - 51.2 
µg/g for the three day maximum fecal concentration (Table 19). 
 The median coefficient of variation of marmoset α1-PI concentrations in fecal extracts 
between the three fecal samples was 23.0% (range: 3.3 – 77.0%). 
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Figure 5. Representative standard curve for the marmoset α1–PI ELISA. The curve is based 
on a five-parameter logistic fit. The seven standards had the following concentrations: 100, 50, 
20, 10, 5, 2, and 1 μg/L. Reprinted with permission.117 
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Table 11. Results of dilutional parallelism for the marmoset serum α1–PI  ELISA shown for 4 
serum samples at dilutions of 1 in 64,000 to 1 in 512,000. Reprinted with permission.117 
Sample ID Dilution  
Observed 
Concentration 
(µg/g) 
Expected 
Concentration 
(µg/g) O/E%  Mean  
Serum 1 
  
  
  
64,000 18.3 N/A N/A 
 
 
 
112.5 
128,000 10.0 9.2 109.5 
256,000 5.2 4.6 114.4 
512,000 2.6 2.3 113.6 
Serum 2 
  
  
  
64,000 18.7 N/A N/A 
 
 
 
112.2 
128,000 10.5 9.4 112.5 
256,000 5.4 4.7 115.5 
512,000 2.5 2.3 108.5 
Serum 3 
  
  
  
64,000 19.5 N/A N/A 
 
 
 
123.0 
128,000 11.0 9.7 112.6 
256,000 6.2 4.9 126.7 
512,000 3.2 2.4 129.8 
Serum 4 
  
  
  
64,000 17.4 N/A N/A 
 
 
 
120.6 
128,000 10.0 8.7 115.3 
256,000 5.3 4.4 121.7 
512,000 2.7 2.2 124.7 
O/E — observed/expected 
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Table 12. Results of dilutional parallelism for the marmoset fecal α1-PI ELISA shown for 4 fecal 
samples at dilutions of 1 in 1,000, to 1in 8,000. Reprinted with permission.117 
Sample 
ID 
Dilution 
Factor  
Observed  
Concentration 
(µg/g) 
Expected 
Concentration 
(µg/g) O/E% Mean 
Fecal 1 
  
  
  
1,000 7.8     
  
  
  
82.6 
2,000 3.9 3.9 100.1 
4,000 1.8 1.9 93.4 
8,000 0.5 1.0 54.2 
Fecal 2 
  
  
  
1,000 24.9     
  
  
  
130.2 
2,000 15.4 12.5 123.6 
4,000 8.4 6.2 134.5 
8,000 4.1 3.1 132.6 
Fecal 3 
  
  
  
1,000 17.4     
  
  
  
110.0 
2,000 9.9 8.7 114.5 
4,000 5.0 4.3 114.6 
8,000 2.2 2.2 100.8 
Fecal 4 
  
  
  
1,000 12.2     
  
  
  
101.5 
2,000 6.9 6.1 112.9 
4,000 3.4 3.0 112.6 
8,000 1.2 1.5 79.0 
O/E — observed/expected 
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Table 13. Results of the spiking recovery for the for marmoset serum α1-PI ELSIA shown for 4 
serum samples spiked with 3 concentrations. Reprinted with permission.117 
Sample 
ID 
Concentration 
added (µg) 
Observed 
Concentration 
(µg/g) 
Expected 
Concentration 
(µg/g) O/E % Mean 
Serum 1 
0  
17.6       
  10 29.1 27.6 105.4   
  25 48.4 42.6 113.7   
  50 86.8 67.6 128.4 115.8 
Serum 2 
0  
21.2       
  10 32.4 31.2 104.2   
  25 49.2 46.2 106.7   
  50 76.6 71.2 107.7 106.2 
Serum 3 
0 
34.0       
  10 45.0 44.0 102.3   
  25 60.0 59.0 101.8   
  50 87.2 84.0 103.8 102.6 
Serum 4 
0  
32.7       
  10 38.5 42.7 90.2   
  25 50.5 57.7 87.4   
  50 68.5 82.7 82.8 86.8 
O/E — observed/expected 
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Table 14. Results for spiking recovery for the for marmoset fecal α1-PI ELSIA shown for 4 fecal 
extracts spiked with 3 concentrations. Reprinted with permission.117 
Sample 
ID 
Concentration 
added (µg) 
Observed 
Concentration 
(µg/ g) 
Expected 
Concentration 
(µg/ g) O/E % Mean 
Fecal 1 0  
10.0       
  10 23.4 20.0 117.0   
  25 43.2 35.0 123.4   
  50 81.0 60.0 135.0 125.1 
Fecal 2 
0  60.2 
      
  10 73.1 70.2 104.2   
  25 82.9 85.2 97.4   
  50 96.9 110.2 88.0 96.5 
Fecal 3 
 0 
10.9       
  10 18.0 20.9 85.8   
  25 28.7 35.9 80.0   
  50 50.7 60.9 83.2 83.0 
Fecal 4 
0  
43.1       
  10 52.4 53.1 98.8   
  25 59.7 68.1 87.7   
  50 69.7 93.1 74.9 87.1 
O/E — observed/expected 
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Table 15. Precision of the ELISA for serum marmoset α1–PI (intra-assay validation). Reprinted 
with permission.117 
  Concentration of Marmoset α1 - Proteinase inhibitor (µg/g)   
Sample ID 1 2 3 4 5 6 7 8 Mean CV% 
Serum 1 32.3 33.8 32.8 33.6 33.2 33.0 32.6 31.1 32.8 2.6 
Serum 2 35.8 37.7 37.4 36.7 35.3 35.9 36.2 37.2 36.5 2.4 
Serum 3 37.6 38.8 37.6 36.4 36.3 37.8 37.1 36.2 37.2 2.4 
Serum 4 33.6 35.0 35.1 37.1 33.7 33.4 34.5 36.8 34.9 4.1 
 CV %: coefficient of variation 
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Table 16. Precision of the ELISA for fecal marmoset α1–PI (intra-assay validation). Reprinted 
with permission.117 
  Concentration of Marmoset α1 - Proteinase inhibitor (µg/g)   
Sample ID 1 2 3 4 5 6 7 8 Mean CV% 
Fecal 1 21.0 21.3 21.6 21.3 20.7 21.1 20.2 20.1 20.9 2.6 
Fecal 2 58.2 57.6 59.0 63.4 55.9 56.9 61.0 67.9 60.0 6.6 
Fecal 3 30.3 30.5 29.4 28.4 28.3 29.1 26.9 26.0 28.6 5.5 
Fecal 4 20.8 21.4 21.7 23.6 19.6 20.9 22.2 24.0 21.8 6.8 
CV : coefficient of variation 
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Table 17. Reproducibility of the ELISA for serum marmoset α1–PI (inter-assay validation). 
Reprinted with permission.117 
  Concentration of Marmoset α1 - Proteinase inhibitor (µg/g) 
Sample ID Run 1 Run 2 Run 3 Run 4 Mean CV (%) 
Serum 1 24.7 25.4 26.6 26.0 25.7 3.1 
Serum 2 28.2 32.7 29.9 29.3 30.0 6.3 
Serum 3 29.7 30.7 30.9 30.7 30.5 1.7 
Serum 4 30.1 30.3 30.4 28.4 29.8 3.1 
 CV %: coefficient of variation 
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Table 18. Reproducibility of the ELISA for fecal marmoset α1–PI (inter-assay validation). 
Reprinted with permission.117 
  
Concentration of Marmoset α1 - Proteinase inhibitor (µg/g) 
Sample Run 1 Run 2 Run 3 Run 4 Mean CV (%) 
Fecal 1 20.0 20.6 23.6 20.2 21.1 8.1 
Fecal 2 52.4 50.0 67.6 56.8 56.7 13.8 
Fecal 3 29.3 30.1 36.2 29.7 31.3 10.4 
Fecal 4 20.3 20.4 22.2 22.3 21.3 5.1 
CV %: coefficient of variation 
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Table 19. Reference intervals established from 30 healthy marmosets using the developed 
ELISA for concentrations of marmoset α1–PI in serum and feces. Reprinted with permission.117 
  Concentration of marmoset α1 - PI 
  
Serum concentration  
(mg/L) 
Three day mean fecal 
concentration (µg/g) 
Three day maximum 
fecal concentration 
(µg/g) 
Reference 
interval  1254.3-1813.5 11.5-42.2 13.2 - 51.2  
Median ± SD 1525.1 ± 158.1 23.8 ± 9.0 29.6 ± 11.5 
Range  1203.0 – 1975.1 9.9 - 46.7 11.4-53.4 
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4.4 Discussion 
 An ELISA for the quantification of marmoset α1-PI in serum samples and fecal extracts  
was successfully developed. The assay was determined to be precise and reproducible for both 
types of biological samples using currently accepted criteria.160 However, the assay does have its 
limitations with respect to linearity and accuracy. Mild deviations (an O/E ratio >120%, but less 
than 130%) from the generally acceptable range of 80% - 120% were observed for dilutional 
parallelism and spiking recovery of serum samples. However, more pronounced deviations were 
seen for fecal samples, for both dilutional parallelism and spiking recovery. This discrepancy in 
performance between serum samples and fecal extracts may be attributable to a possible matrix 
effect when using fecal extracts. The greatest underestimation of α1-PI concentrations occurred 
when the expected concentration was less than 2 ng/g of feces during dilutional parallelism (O/E% 
of 54.2%, and 79%); given that the intent of the assay was to detect increases in fecal 
concentrations of marmoset α1-PI as evidence of gastrointestinal protein loss, issues with linearity 
in samples with a concentration less than 2 ng/g of feces should not detract from the clinical 
usefulness of the assay. The specific reason for over-recovery of this assay is unknown. However 
this problem is generally attributed to the presence of high-affinity antibodies.14   
 The reference interval for concentrations of marmoset α1-PI in serum was from 1,254 -
1,814 mg/L. This is comparable with serum α1-PI concentration reported in other species such as 
the dog, cat, and human, which are 732-1802 mg/L,59 250-600mg/L,44 and 900-1200mg/L,93 
respectively.  
 Fecal α1-PI concentrations in healthy cats are reported to be from 0.04 (or undetectable) to 
1.72 μg/g (median: 0.51 μg/g) and in healthy adult dogs from <2.2 to 26.8 µg/g (median: 4.7 µg/g). 
In the 30 healthy marmosets in this study fecal α1-PI concentrations were much higher and ranged 
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from 11.4 to 48 µg/g (median: 27.1 µg/g) for samples collected on day 1. A reason for this 
increased concentration is unknown.  
 As reported for dogs58 and cats26, a similarly high %CV was also observed in the common 
marmoset within the 3-day fecal samples (median: 26.3%, minimum-maximum 3.4% - 77.0%), 
i.e., there is considerable day to day variation of fecal α1-PI concentrations. This justifies the need 
for a 3 consecutive fecal collections in this species.  
 An important limitation of this study is the low number marmosets in the reference sample 
group for both fecal extracts and serum samples. Ideally, reference intervals are calculated from 
results from approximately 120 healthy individuals. However, samples form 30 marmosets were 
all that was available to us. As samples were limited, we did not further investigate the effect of 
storage or repeated freeze-thaw cycles on the recovery of marmoset α1-PI concentrations in serum 
samples or fecal extracts. As there were only limited numbera of samples available for validation 
purposes a relatively narrow range of concentrations was represented that did not span the whole 
working range of the assay. Validation with samples with a wider range would have been 
preferable, but this was not feasible.  
 In conclusion, the marmoset α1-PI ELISA described here is sensitive, precise, and 
reproducible with suboptimal linearity for fecal samples less than 2 ng/g, and suboptimal accuracy, 
as assessed by spiking recovery, at the either end of the assay working range. Additional clinical 
studies are necessary to determine the clinical utility of this assay for detecting protein losing 
enteropathy in marmosets.  
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CHAPTER V 
FECAL ALPHA1-PROTEINASE INHIBITOR CONCENTRATIONS IN COMMON 
MARMOSETS (CALLITHRIX JACCHUS) WITH CHRONIC LYMPHOCYTIC ENTERITIS. 
 
5.1 Introduction 
The common marmoset (Callithrix jacchus) is a New World primate originally from Brazil. 
Its small size, easy maintenance, absence of certain zoonotic diseases, multiple births at each 
parturition, and relatively short lifespan make it a popular species for biomedical research.90,1 
Chronic lymphocytic enteritis (CLE) is endemic to marmoset research colonies, with the reported 
prevalence varying from 28–60 % in the laboratory setting.88  Clinically, CLE it is associated with 
chronic progressive weight loss in adults and unthriftiness in juveniles. Diarrhea, mild anemia, and 
low serum protein concentrations are common, with affected marmosets either dying or being 
euthanized.11,88 The disease currently can only be confirmed upon necropsy.  
A non-invasive fecal test to detect enteric protein loss may allow early ante-mortem 
diagnosis and could facilitate screening and removal of affected marmosets in research colonies. 
Alpha1-proteinase inhibitor (α1-PI) is a serum protein that is only lost into the gastrointestinal tract 
in minimal quantities in healthy individuals. It's molecular weight is similar to that of albumin, but 
it is resistant to degradation by digestive and bacterial enzymes within the gut. Intact α1-PI can be 
detected by fecal immunoassays and the assay has previously been employed to detect increased 
enteric protein loss in humans, 22 dogs,96 and cats.25 Recently, two immunoassays, a 
radioimmunoassay (RIA) and a sandwich enzyme-linked immunosorbent assay (ELISA) for 
measuring the concentrations of α1-PI in serum and fecal extracts from the common marmoset 
have been developed and analytically validated.  
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The aim of this study was to determine if fecal concentrations of α1-PI were increased in 
marmosets with CLE, suggesting a protein losing enteropathy.  
 
5.2 Materials and methods 
5.2.1 Agreement between the RIA and the ELISA 
To assess the agreement between results obtained by the newly developed immunoassays, 
RIA and ELISA, the results of fecal α1-PI concentrations from 47 common marmosets from three 
different primate centers [NEPRC (n=17), Southwest National Primate Research Center; Texas 
Biomedical Research Institute, Texas (n=17), and the Barshop Institute for Longevity & Aging 
Studies University of Texas Health Science Center, Texas (n=14)] were compared. The 
concentrations of fecal α1-PI obtained in the RIA were plotted against those determined using the 
ELISA, and a Spearman correlation coefficient (ρ) was calculated. This was followed by a Tukey 
mean‐difference plot (Bland–Altman plot) to look for biases.  Based on these results, one 
immunoassay was chosen for the study.  
 
5.2.2 Marmoset fecal samples  
Fecal samples from marmosets previously submitted to the Gastrointestinal Laboratory at 
Texas A&M University for research purposes (n=10) and fecal samples collected at necropsy 
(n=15) from common marmosets euthanized as a part of routine colony management procedures 
at the New England Primate Research Center (NEPRC), Southborough, MA were stored at -80oC 
and shipped on dry ice and were used for the study.  
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Clinical history and necropsy records were obtained and reviewed for these animals to 
ascertain cause of death. This was done after the assay was completed, in order to avoid any bias. 
Necropsies were performed by a board certified anatomic pathologist at the NEPRC. 
 
5.2.3 Extraction of fecal samples and RIA 
Fecal samples were thawed and then extracted as previously described to generate the fecal 
extract (Chapter 3). Fecal extracts were stored at –80°C until analysis. Stored fecal extracts were 
thawed and diluted 1:200 in radioimmunoassay buffer. Samples were run using the previously 
validated marmoset α1-PI radioimmunoassay procedure (Chapter 3). The results were compared 
to the previously established, three-day mean fecal α1-PI concentration reference interval. 
 
5.2.4 Statistical analyses 
Statistical analyses were performed using GraphPad Prism 5.0 [GraphPad Software, Inc., 
San Diego, CA) and statistical significance was set at P < 0.05. 
 
5.3 Results 
The concentrations of fecal α1-PI measured in 47 marmoset samples by use of the RIA 
were only moderately positively correlated to the results of the ELISA as indicated by a Spearman 
ρ of 0.71 (P <  0.0001) [Figure 6]. The difference between both immunoassays was plotted against 
their mean (Bland–Altman plot; Figure. 7) with a mean difference of -20. Given the discrepancy 
between the two immunoassays for the same samples and the validation of the RIA being more 
robust compared to the ELISA, we decided to use the RIA to determine if marmosets with CLE 
had increased concentrations of fecal α1-PI. 
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Figure 6. Correlation of fecal α1-PI concentrations (µg/g) measured in 47 fecal samples from 
marmosets using both the radioimmunoassay and the ELISA. The two assays were moderately 
correlated (Spearman ρ of 0.71, P <0.0001). 
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Figure 7. Bland–Altman plot. Each symbol represents the difference between both methods against 
their mean for a specific fecal sample (n = 47). The mean difference (bias) was calculated as -
20.46 (95% confidence interval [CI]: -54.99 to 14.08). 
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For a total of 25 marmosets fecal α1-PI concentrations and necropsy findings were 
available, and among those 15 also had a clinical history available. Of these marmosets, 11 had 
CLE, 9 had other diseases (i.e., chronic kidney disease (5), cholecystitis (2), pancreatitis (1), 
lymphoma and ulcerative enteritis (1), enteropathogenic E. Coli (1), and small intestinal 
adenocarcinoma (1)), and 5 were healthy. Fecal α1-PI concentrations were not significantly 
different between the three groups (Kruskal–Wallis test, P = 0.50).  
Other diseases observed in these marmosets included conditions, such as intestinal 
adenocarcinoma, that could also lead to an intestinal protein loss, thereby increasing fecal α1-PI 
concentrations. The marmosets were again regrouped into healthy marmosets (5), those with 
diseases that might be associated with intestinal protein loss (14), and those with diseases not 
associated with intestinal protein loss (6). Fecal α1-PI concentrations were not significantly 
different between these three groups (Kruskal–Wallis test, P = 0.75). 
Only one marmoset with renal disease had a fecal α1-PI concentration greater than the 3-
day-mean of 234.0 µg/g of feces as reported in healthy marmosets. Necropsy findings on this 
marmoset’s intestinal tract showed one section of the proximal jejunum with a single dilated crypt 
filled with cellular debris and few degenerate neutrophils. The cecum and the colon showed 
minimal to low numbers of lymphocytes and plasma cells within the mucosa, and the cecum had 
multifocal areas of mild crypt regeneration.  
 
5.4 Discussion 
This study failed to show a significant increase in fecal concentrations of α1-PI in common 
marmosets with chronic lymphocytic enteritis, based on previously established reference intervals 
for the common marmoset. These findings are in contrast to dogs where increased fecal 
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concentrations of α1-PI have been reported in patients with gastrointestinal disease, particularly 
those with IBD and lymphangectasia,107 acute hemorrhagic diarrhea syndrome,57 parvoviral 
gastroenteritis,104 tylosin responsive diarrhea,164 and also in healthy sled dogs after a race.39 In cats, 
increased fecal concentrations of α1-PI have been reported in patients with severe IBD or 
confirmed gastrointestinal neoplasia.25 In humans, increased fecal concentrations of α1-PI have 
been reported in a variety of gastrointestinal disorders,149 and also as an indicator of Crohn's 
disease activity.99 A good correlation has been reported between the gold standard, 51Cr-albumin 
excretion and fecal α1-PI in humans123 and in dogs.94 However, it has been reported to have a poor 
sensitivity (58%), with a good specificity (80%), limiting its use in humans.123 It remains unknown 
if lower concentrations of fecal α1-PI in the common marmoset are a result of this low sensitivity. 
Normal concentrations of fecal α1-PI were unexpected in this study. It has previously been 
shown that increased gastric acid secretion can lead to decreased fecal α1-PI concentrations. 
However, this would seem to be an unlikely explanation in the marmosets as marked increased 
gastric acid secretions would have led to lesions in the stomach, that would have been observed 
upon necropsy.  
Alpha1-PI in humans is excreted in the feces in two forms, a protease-antiprotease complex, 
but also as an unchanged α1-PI  when compared to serum.24 The proportion of these two products 
are variable between individuals and an increased presence of protease-antiprotease complex 
might lead to a false decrease in the apparent fecal α1-PI concentration. This effect has been 
observed in an in-vitro study using canine α1-PI  spiked with bovine trypsin.95  
It is interesting to note that in the one marmoset with renal failure, elevated fecal α1-PI 
concentrations with no, or minimal changes of gastrointestinal histopathologic morphology did 
have decreased serum cobalamin and folate concentrations of <150 pg/mL and 28.3 ng/mL, 
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respectively. These results are much lower than the established reference intervals of 322 – 2,642 
pg/mL and 54.8 – 786.4 ng/mL for serum cobalamin and folate concentrations, respectively. 
Decreased serum cobalamin and folate concentrations do suggest diffuse small intestinal disease, 
but histological confirmation was not achieved in this case. A focal area with ulceration or 
inflammation leading to enteric protein loss could still be present, and it could have been in an area 
of gut that was not sectioned. The clinical history of this marmoset also indicated progressive 
weight loss and a chronic anemia for over a year, both of which have been reported in marmosets 
with CLE. However, these clinical signs are non-specific and can also be associated with chronic 
kidney disease in older marmosets. The marmoset was 4,667 days, approximately 13 years, old, 
which is the approximate life span of common marmosets in captivity.  
The RIA validation study (Chapter 3) did not explore the effect of storage conditions on 
the concentrations of fecal α1-PI in the marmoset, and assumed that freezing helped to preserve 
fecal α1-PI in the common marmoset, which was extrapolated from canine studies.96 Another factor 
for the lack of increased fecal α1-PI concentrations detected in this study could be that while the 
feces remained in the animal after euthanasia or death, the protein in the fecal sample could have 
been denatured or destroyed by the body’s autolytic process. The exact time from death to necropsy 
was unknown, with the median being zero days but it ranged from 0-3 days based on medical 
records. All necropsies had an associated form with a check box to indicate degree of autolysis, 
and all were marked as fresh. Interestingly, the marmoset with greatest concentration of fecal α1-
PI, had the greatest time recorded of three days, suggesting that a falsely decreased fecal α1-PI 
concentration because of fecal collection at delayed necropsy was an unlikely cause for lower α1-
PI concentrations.  
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Fecal samples used in this study were collected from the rectum at necropsy and frozen, 
versus naturally passed samples used to establish the reference interval in healthy marmosets. It 
has been shown in dogs that rectal collection159 does increase fecal α1-PI concentrations, 
presumably due to the presence of blood. However, this is controversial in the human 
literature.54,156 Given the lack of increase in fecal α1-PI concentrations in these marmosets, it is 
unlikely that the method of collection affected these results. 
Only a limited number of samples were available to establish the earlier reference intervals 
for fecal α1-PI (Chapter 3) and they were primarily from two different centers other than the 
NEPRC. Animals that were used to establish the reference interval were presumed to be healthy 
based on the absence of clinical signs. However, given how little is known about the disease, 
subclinical chronic lymphocytic enteritis could not be ruled out as gastrointestinal biopsies were 
not available. Thus, it is possible that the reference interval may have to be revisited.  
Limitations of this study include a single time point for fecal sample collection, which may 
not have been appropriate given the relatively high coefficient of variation (median 21.4%, Range 
2.9 – 74.3%) between the three-day fecal samples reported in the earlier study, and this has also 
been reported in other species such as the dog.58 Larger studies looking at single time point and 
three-day fecal collections should be performed. Serum protein, and albumin concentration data 
were also not available for these marmosets.  
 To conclude, fecal α1-PI concentrations were not significantly increased in a small 
population of common marmosets with CLE. Larger studies are needed to determine the utility of 
fecal α1-PI concentrations in marmosets with gastrointestinal disease, particularly CLE. 
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CHAPTER VI 
SERUM COBALAMIN AND FOLATE CONCENTRATIONS IN COMMON MARMOSETS 
(CALLITHRIX JACCHUS) WITH CHRONIC LYMPHOCYTIC ENTERITIS.∞ 
 
6.1 Introduction 
The common marmoset (Callithrix jacchus) is a Brazilian New World monkey that has 
been employed in biomedical research since the early 1970’s.1 Marmosets are a popular species 
for biomedical research because of their small size (350-450g), relatively low cost for 
maintenance, easy husbandry, easy habituation to routine clinical procedures, rapid reproductive 
turnover, and low incidence of zoonoses. Currently, marmosets are used for research in the fields 
of neuroscience, reproductive biology, infectious diseases, behavior, drug development and safety 
assessment, and aging research.90  
Inflammatory diseases of the intestinal tract, particularly colitis and inflammatory bowel 
disease (IBD), particularly chronic lymphocytic enteritis (CLE) has been a consistent finding in 
several colonies of marmosets.32,38,158 Between 1991 and 2000, about 60.5% of all non-
experimental marmosets at the New England Primate Research Center (NEPRC), Southborough, 
MA had some degree of IBD.154 Similarly, from 2002-2011 at the Southwest National Primate 
Research Center, Texas Biomedical Research Institute, San Antonio (SNPRC) facility, 31%-44% 
of marmoset deaths were attributed to IBD.131 To date, no specific etiology has been proven for 
this disease in the marmoset. However, many factors such as gluten sensitivity, dietary protein 
deficiency, and pancreatic duct parasitism (Trichospirura leptostoma) have been speculated to  
∞Submitted to Comparative Medicine. Parambeth JC, Ross C, Miller A, Austad SN, Lidbury JA, 
Suchodolski JS, Steiner JM. Serum cobalamin and folate concentrations in common marmosets 
(Callithrix jacchus) with chronic lymphocytic enteritis. 
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play a causal role.27 CLE is characterized histologically by diffuse to segmental lymphocytic 
enteritis. Clinically, it manifests itself by failure to thrive in juveniles or weight loss in adults with 
or without diarrhea.88 Currently, a presumptive ante-mortem diagnosis is made based on consistent 
clinical signs, a history of weight loss, and a decreased serum albumin concentration.11 Fecal 
calprotectin,108 serum matrix metalloproteinases,171 serum IgA antibodies against gliadin and 
related proteins84 have been measured in marmosets with CLE and may serve as diagnostic 
markers in the future. To date, no treatment  has been shown to be effective and a definitive 
diagnosis is usually made at necropsy.88  
Cobalamin (vitamin B12) is a water soluble vitamin that is an essential co-factor for the 
enzymes methylmalonyl CoA mutase, methionine synthase, and methylmalonyl-coA mutase. 
Intestinal uptake of cobalamin is a multistep process, with absorption of cobalamin-intrinsic factor 
complexes occurring through specific receptors on ileal enterocytes.91,150 Cobalamin deficiency is 
reported frequently in dogs and cats with exocrine pancreatic insufficiency, distal small intestinal 
disease, or diffuse small intestinal disease, and is less commonly attributed to genetic defects in 
certain dog breeds.47 Exocrine pancreatic insufficiency causes hypocobalaminemia in dogs as the 
majority of intrinsic factor in dogs is synthesized by pancreatic acinar cells.9,35 Ileal disease is 
believed to lead to damage or decreased expression of cobalamin receptors, ultimately leading to 
reduced cobalamin absorption and deficiency once cobalamin body stores have been used up. 
Intestinal dysbiosis can also lead to decreased serum cobalamin concentrations as many bacterial 
species compete for and bind available cobalamin.49 The reported prevalence of cobalamin 
deficiency in dogs and cats with gastrointestinal disease ranges from 6 - 18.5% in dogs5,35 and 
from 17 - 61% in cats.128,141 Furthermore, hypocobalaminemia has been associated with negative 
outcomes in dogs with chronic enteropathy5 or exocrine pancreatic insufficiency,8 and cobalamin 
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supplementation may have  therapeutic potential.132 Decreased serum cobalamin concentrations 
have been reported in cats with exocrine pancreatic insufficiency,168 IBD, and gastrointestinal 
neoplasia such as lymphoma and adenocarcinoma.71 To the best of our knowledge, no data on the 
cobalamin status of marmosets has been reported to date. However, recently serum cobalamin 
concentrations have been investigated in rhesus macaques and pigtailed macaques with chronic 
idiopathic diarrhea.21 Serum cobalamin concentrations were 2.5 fold lower in pigtailed macaques 
with chronic idiopathic diarrhea compared to healthy controls. However, no difference was 
observed in rhesus macaques.21  
Folate (B9) is also a water-soluble B complex vitamin. Dietary folate in the form of folate 
polyglutamate is poorly absorbed in the intestinal tract. However, the enzyme, folate deconjugase 
in the jejunal brush border converts folate polyglutamate into monoglutamate, which is then 
absorbed into enterocytes of the proximal small intestine utilizing specific carriers. Chronic 
intestinal disease damages folate carriers, reducing folate uptake, and thus leading to decreased 
serum concentrations of folate.146 Increased serum folate concentrations are reported in dogs with 
intestinal dysbiosis as many bacterial species synthesize folate.49 In addition, chronic enteropathy 
also can lead to decreased serum folate concentrations in dogs and cats.35,128 To the best our 
knowledge, serum folate concentrations have not been evaluated in marmosets with or without 
gastrointestinal disease.  
Dietary deficiency of cobalamin and folate is highly improbable, and it is believed that 
even withholding food for several weeks duration does not cause serum cobalamin and folate to 
become subnormal.146 Rather, characterizing the changes in serum concentrations of cobalamin 
and folate in marmosets with CLE may help facilitate monitoring gastrointestinal health in this 
species.  The objective of this study was 1) to partially validate commercially available 
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immunoassays for the measurement of cobalamin and folate in human serum for use in the 
common marmoset, 2) to establish reference intervals for serum concentrations of cobalamin and 
folate in healthy common marmosets, and 3) to study the changes in the concentration of serum 
cobalamin and folate in marmosets with CLE.  
 
6.2 Materials and Methods 
6.2.1 Marmoset serum samples and data 
This study was approved by the respective primate centers’ Institutional Animal Care 
Committees. Serum samples were collected from common marmosets from the Southwest 
National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, 
Texas (AUP # 1259CJ), and the Barshop Marmoset Aging Center (BMAC), The University of 
Texas Health Science Center, San Antonio, Texas (06120X). Additionally, left over serum samples 
submitted to the Gastrointestinal Laboratory, Texas A&M University as part of diagnostic testing 
from the common marmoset colony at the New England Primate Research Center (NEPRC), 
Southborough, MA were also used in the study. Serum samples were transported on dry ice to the 
Gastrointestinal Laboratory, and stored at -80oC until analysis. 
Clinical history, and/or necropsy data from these common marmosets were reviewed to 
determine if they were healthy at the time of collection, had clinical signs of gastrointestinal 
disease, or had histopathological evidence of CLE.  
  
6.2.2 Analysis of serum cobalamin and folate concentrations 
Serum cobalamin and folate concentrations were measured using competitive 
chemiluminescence enzyme immunoassays (IMMULITE® 2000, Siemens, IL) approved for use 
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in humans. The reportable range of the cobalamin assay is 150-1,000 pg/mL and the reportable 
range for the folate assay is 1-24 ng/mL. Samples that had results over this reportable range were 
diluted with the sample diluent (# L2FVZ) supplied with the assay kits as per the manufacturer’s 
recommendations. 
 
6.2.3 Partial validation 
Since no validation data was available for non-human primates, a partial validation for the 
assays was performed. Due to the small serum sample volumes available from individual common 
marmosets, serum samples were pooled to obtain sufficient volumes for assay validation. Four 
pooled serum samples were used for analytical validation. 
Linearity of the assay was determined by dilutional parallelism. Four pooled serum samples 
were serially diluted (1:2, 1:4, 1:8, and 1:16) manually. The observed to expected ratio was 
calculated and expressed as a percentage (% O/E). The Immulite instrument is able to perform 
sample dilutions during runs, and this was included as a part of validation too. Four individual 
serum samples were run using dilutions available on the Immulite of 1:3, 1:5, 1:10, and 1:20 for 
the cobalamin validation. Five individual serum samples were run using dilutions available on the 
Immulite of 1:10, 1:20, 1:40, and 1:100 for the folate validation. The % coefficient of variation 
(CV% = standard deviation / mean*100) was reported by the Immulite.  
Accuracy of the assay was determined by mixing three pooled samples with other pooled 
samples of known concentrations in a 1:1 ratio. Standard recovery was calculated from the ratio 
of observed concentration to expected concentration expressed as a percentage (% O/E). Spiking 
was also carried out using three QC controls provided with the assay in a 1:1 pattern to four serum 
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samples for the cobalamin assay and five serum samples for the folate assay. The observed-to-
expected ratios were calculated as before.  
Precision was determined by evaluating 4 pooled serum samples, 5 times on the same run, 
on the same day. Reproducibility was determined by evaluating 4 pooled serum samples, 5 times 
on different runs on consecutive days. Both precision and reproducibility were assessed by 
calculating the coefficient of variation (CV% = standard deviation / mean*100).  
 
6.2.4 Stability testing  
To assess the stability of serum cobalamin and folate samples stored at -80oC, six samples 
analyzed in 2006 for serum cobalamin and folate concentrations were rerun in 2013.  
 
6.2.5 Reference intervals  
Reference intervals for serum cobalamin and folate were established by utilizing RefVal 
2.1 (Department of Clinical Chemistry, Rikshospitalet, N-0027 Oslo, Norway) adapted for 
Microsoft Excel (Microsoft, Redmond, WA, USA), using samples from healthy marmosets with 
no previous history of gastrointestinal disease based on clinical history from two centers (BMAC 
& SNPRC).  
 
6.2.6 Additional analysis 
Metadata from the two primate centers (BMAC & SNPRC) was analyzed for serum 
concentrations of cobalamin and folate; particularly looking at location of housing, age in days 
(when sample was collected), sex, dam, sire, birthplace, litter size, weaning litter size, adult body 
weight, obesity status (as determined as function of body weight), and age group. Marmosets were 
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divided based on their age groups into infant (0 – 5 months), juvenile (5 – 10 months), sub-adult 
(10 – 15 months), and young adult (> 15 months).170  
Serum cobalamin and folate concentrations were compared between healthy marmosets 
and those with any clinical history of gastrointestinal disease based on medical records from these 
two centers. Repeated measurements of serum cobalamin and folate from the same animals where 
available were analyzed over fixed time points.  
 
6.2.7 Analysis using samples from the NEPRC 
The established reference intervals were used to assess concentrations of serum cobalamin 
and folate in another marmoset colony (NEPRC), where cross sectional and longitudinal 
measurements were already available. Based on necropsy diagnosis, marmosets from the NEPRC 
were categorized as healthy, having CLE, or other diseases as the cause of death. Serum cobalamin 
and folate concentrations were compared between these three groups.   
 
6.2.8 Sensitivity and specificity  
Sensitivity and specificity were calculated using an online calculator 
(https://www.medcalc.org/calc/diagnostic_test.php). Sensitivity was calculated by the formula: a 
/ (a+b) X 100, and specificity was calculated by the formula: d / (c+d) X 100; where a = marmosets 
with CLE and a low serum cobalamin and/or folate concentration, b =  marmosets with CLE with 
normal serum cobalamin and folate concentrations, c =  marmosets without CLE, but with a low 
serum cobalamin and/or folate concentrations, and d = marmoset without CLE and normal serum 
cobalamin and folate concentrations.  
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6.2.9 Statistics analysis 
Statistical analyses were performed using commercially available software packages (JMP 
10, SAS Institute Inc., Cary, NC and GraphPad PRISM 5.00, GraphPad Software, Inc. La Jolla, 
CA). Significance was set at P<0.05. Normality was tested using the Shapiro–Wilk test, which 
was not met. Where multiple parameters were evaluated, a Bonferroni correction was applied. 
Wilcoxon signed-rank test was used for repeated measures. Mann-Whitney U and Kruskal-Wallis 
tests with a Dunn’s post-test were used to compare between groups. 
 
6.3 Results 
6.3.1 Validation 
For the cobalamin measurements: observed-to-expected ratios for 1:1, 1:2, and 1:4 
dilutions ranged from 113.2 to 282.2% (mean ±SD: 176.21 ±67.29 %) (Table 20). The CV% for 
the concentrations of serum cobalamin using dilutions available on the Immulite were 3.8%, 5.8%, 
7.0%, and 8.8% for the 4 serum samples at three different dilutions at 1:3, 1:5, and 1:10. At a 
dilution of 1:20, the samples were too dilute and hence failed to give a result (Table 21). Observed-
to-expected ratios for spiking recovery ranged from 91.5 to 96.3% (mean ±SD: 93.76 ± 1.98 %) 
for three serum samples being spiked with serum samples of different concentrations (Table 22). 
Observed-to-expected ratios for spiking recovery ranged from 92.9 to 105.9 % (mean ±SD: 98.2 
± 5.7 %) for four serum samples, using 122.0, 276.0, and 425.5 pg of cobalamin from the quality 
control sample provided by the manufacturer (Table 23). Intra-assay coefficient of variation (% 
CV) ranged from 0.4 - 3.4%. Inter-assay coefficient of variation (%CV) ranged from 3.5 - 8.4% 
(Table 24). The analytical sensitivity for this assay is reported to be 125 pg/mL by the 
manufacturer.  
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Table 20. Results for manually prepared dilutional parallelism of serum samples for serum 
cobalamin concentrations in the marmoset. Reprinted with permission.119 
 Dilution 
Observed 
(pg/mL) 
Expected 
(pg/mL) 
O/E (%) 
Serum 1 0 485   
 1:2 283 242.5 116.7 
 1:4 167 121.3* N/A 
 1:8 165 60.6* N/A 
 
Serum 2 0 391   
 1:2 262 195.5 134.0 
 1:4 188 97.8* N/A 
 1:8 <150 48.9* N/A 
 
Serum 3 0 202   
 1:2 163 101.0* N/A 
 1:4 <150 50.5* N/A 
 1:8 <150 25.3* N/A 
 
Serum 4 0 456   
 1:2 258 228.0 113.2 
 1:4 182 64.5* N/A 
 1:8 <150 57.0* N/A 
* indicates that the concentration is below the lower limit of detection of the assay.  
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Table 21. Results for automatically prepared dilutional parallelism for serum cobalamin 
concentrations in the marmoset. Reprinted with permission.119 
Serum 
sample 
Dilution used on the 
Immulite 
Observed Vitamin B12 
concentration (pg/mL) 
Coefficient of variation 
(%) between samples 
Serum 1 
1:3 1580 
5.8 
1:5 1392 
1:10 1580 
1:20 N/A 
  
Serum 2 
1:3 1708 
7.0 
1:5 1445 
1:10 1644 
1:20 N/A 
  
Serum 3 
1:3 1923 
8.8 
1:5 1728 
1:10 1550 
1:20 N/A 
  
Serum 4 
1:3 1665 
3.8 
1:5 1538 
1:10 1674 
1:20 N/A 
 100 
  
Table 22. Results for spiking recovery of serum samples with other serum samples with known 
serum cobalamin concentrations. Reprinted with permission.119 
Spiking 1:1 
Expected 
(pg/mL) 
Observed 
(pg/mL) 
O/E 
(%) 
Serum 1: Serum 3 340.1 318.0 93.5 
Serum 2: Serum 3 293.0 268.0 91.5 
Serum 3: Serum 4 325.0 313.0 96.3 
Cobalamin concentrations were 486.6pg/mL, 392.4pg/mL, 193.6pg/mL, and 456.4pg/mL for 
serum 1, serum 2, serum 3, and serum 4 respectively. 
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Table 23. Results for spiking recovery of serum samples using cobalamin Immulite standards 
(QC). Reprinted with permission.119 
Serum 
sample 
Concentration 
of spiking 
solution 
(pg/mL) 
Observed* 
cobalamin 
concentration 
(pg/mL) 
Expected* 
cobalamin 
concentration 
(pg/mL) 
O/E % O/E % 
Serum 1 
0 (diluent) 297     
92.9 
244 374 419 89.3 
552 513 573 89.5 
851 722 722.5 99.9 
Serum 2 
0 (diluent) 263     
95 
244 356 385 92.5 
552 502 539 93.1 
851 685 688.5 99.5 
Serum 3 
0 (diluent) 257     
105.9 
244 378 379 99.7 
552 551 533 103.4 
851 783 682.5 114.7 
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Table 23. Continued 
Serum 
sample 
Concentration 
of spiking 
solution 
(pg/mL) 
Observed* 
cobalamin 
concentration 
(pg/mL) 
Expected* 
cobalamin 
concentration 
(pg/mL) 
O/E % O/E % 
Serum 4 
0 (diluent) 278     
99 
244 388 400 97 
552 570 554 102.9 
851 683 703.5 97.1 
 *100µL of the spiking solution was added to 100µL of the serum samples.  
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Table 24: Precision and reproducibility for the measurement of serum cobalamin concentrations 
in the common marmoset using the Immulite cobalamin assay. Reprinted with permission.119 
Sample 
Number of 
repeats  
Mean 
(pg/mL) 
Standard 
deviation 
(pg/mL) 
Coefficient of 
variation  
(%) 
Intra-assay variability 
Serum 1 5 449.8 15.6 3.5 
Serum 2 5 353.4 26.4 7.5 
Serum 3 5 172.8 14.5 8.4 
Serum 4 5 450.2 24.0 5.3 
Inter-assay variability 
Serum 5 5 486.6 15.9 3.3 
Serum 6 5 392.4 1.7 0.4 
Serum 7 5 193.6 6.4 3.3 
Serum 8 5 456.4 15.4 3.4 
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For the folate measurements: observed-to-expected ratios for 1:1, 1:2, 1:4, and 1:8 dilutions 
ranged from 63.0 to 95.0% (mean ±SD: 73.10 ±9.68%) (Table 25). The CV% for the 
concentrations of serum folate using dilutions available on the Immulite were 8.7%, 9.2%, 11.9%, 
16.9%, and 20.6% for the 5 serum samples at four different dilutions of 1:10, 1:20, 1:40, and 1:100 
(Table 26). Observed-to-expected ratios for spiking recovery ranged from 90.1 to 103.2% (mean 
± SD: 96.99 ± 6.59%) for three serum samples being spiked with other serum samples with 
different concentrations (Table 27). Observed-to-expected ratios for spiking recovery ranged from 
75.0 to 101.4 % (mean ±SD: 85.3 ± 4.6 %) for the five serum samples, using 1.5, 7.0, and 10.9 ng 
of folate from the quality control sample provided by the manufacturer (Table 28). The intra-assay 
coefficient of variation (%CV) ranged from 1.8 - 9.4%. Inter-assay coefficient of variation (%CV) 
ranged from 3.7 - 5.9% (Table 29). The analytical sensitivity for this assay is 0.8 ng/mL as reported 
by the manufacturer. 
No statistically significant differences in cobalamin and folate concentrations in six serum 
samples stored at -80oC between 2006 and 2013 were identified (P = 0.58, P = 0.81 respectively). 
The median [minimum – maximum] CV% for the cobalamin and folate concentrations for the six 
serum samples for the measurements made in 2006 and 2013 were 10.5% [2.9 - 21.9%], and 12.5% 
[2.5 - 22.8%]. 
6.3.2 Reference intervals 
Serum samples from a total of 53 marmosets were available, 34 of which were from the 
BMAC and 19 from the SNPRC. Of these animals, 14 marmosets (BMAC 8, SNPRC 6) had a 
history of clinical signs associated with gastrointestinal disease, and were excluded from  
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Table 25. Results for manually prepared dilutional parallelism of serum samples for serum folate 
concentrations in the marmoset. Reprinted with permission.119 
Dilution 
Observed (O)  Expected (E)  
O/E (%) 
ng/mL ng/mL 
Serum 1       
1:1 13.1     
1:2 5.4 6.6 82.3 
1:4 2.1 3.3 63.8 
1:8 1.1 1.6 64.7 
Serum 2       
1:1 17.9     
1:2 7 9 77.9 
1:4 2.9 4.5 64.8 
1:8 1.4 2.2 63 
Serum 3       
1:1 9.6     
1:2 3.4 4.8 70.6 
1:4 1.6 2.4 66.9 
1:8 <1.0* 1.2   
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Table 25. Continued 
Dilution 
Observed (O)  Expected (E)  
O/E (%) 
ng/mL ng/mL 
Serum 4       
1:1 20.6     
1:2 9.8 10.3 95 
1:4 4.2 5.2 81.7 
1:8 1.9 2.6 73.4 
* indicates that the concentration is below the lower limit of detection of the assay. 
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Table 26. Results for automatically prepared dilutional parallelism for serum folate concentrations 
in the marmoset. Reprinted with permission.119 
Serum sample 
Dilution used on 
the Immulite 
Observed 
folate 
concentration 
(ng/mL) 
Coefficient of 
variation (%) 
between samples 
Serum 1 
1:10 - 
8.7 
1:20 - 
1:40 629 
0.11111 556 
  
Serum 2 
1:10 209 
20.6 
1:20 179 
1:40 160 
1:100 126 
  
Serum 3 
1:10 - 
11.9 
1:20 - 
1:40 488 
1:100 412 
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Table 26. Continued 
Serum sample 
Dilution used on 
the Immulite 
Observed 
folate 
concentration 
(ng/mL) 
Coefficient of 
variation (%) 
between samples 
Serum 4 
1:10 - 
9.2 
1:20 322 
1:40 316 
1:100 271 
  
Serum 5 
1:10 - 
16.9 
1:20 - 
1:40 675 
1:100 690 
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Table 27. Results for spiking recovery of serum samples with other serum samples with known 
serum folate concentrations. Reprinted with permission.119 
Spiking 1:1 
Expected (E) 
folate 
concentration 
(ng/mL) 
Observed (O) 
folate 
concentration 
(ng/mL) 
O/E 
(%) 
Serum 1: Serum 2 11.4 11.1 97.7 
Serum 1: Serum 3 13.8 12.4 90.1 
Serum 1: Serum 4 15.1 15.6 103.2 
 Folate concentrations were 9.6 ng/mL, 13.1 ng/mL, 17.9 ng/mL, and 20.6 ng/mL for serum 1, 
serum 2, serum 3, and serum 4 respectively. 
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Table 28. Results for spiking recovery of serum samples using folate Immulite standards (QC). Reprinted with permission.119 
Serum 
sample 
Concentration 
added (ng) 
Observed folate 
concentration 
(ng/mL) 
Expected folate 
concentration 
(ng/mL) 
O/E % O/E% 
Serum 1 - 6.3       
  1.5 7.7 7.8 98.2   
  7.0 9.4 13.3 70.7 82.2 
  10.9 13.4 17.2 77.8   
Serum 2 - 1.2       
  1.5 2.9 2.7 109.6   
  7.0 6.0 8.2 72.9 86.1 
  10.9 9.1 12.1 75.7   
Serum 3 - 5.4 5.4     
  1.5 6.5 7.0 93.2   
  7.0 9.7 12.5 77.6 81.8 
  10.9 12.2 16.3 74.7   
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Table 28. Continued 
Serum 
sample 
Concentration 
added (ng) 
Observed folate 
concentration 
(ng/mL) 
Expected folate 
concentration 
(ng/mL) 
O/E % O/E% 
Serum 4 - 3.2       
  1.5 3.9 4.7 82.6   
  7.0 7.0 10.2 67.9 75.0 
  10.9 10.5 14.1 74.3   
Serum 5 - 4.2       
  1.5 3.8 5.7 66.9   
  7.0 14.5 11.2 129.3 101.4 
  10.9 16.3 15.1 107.9   
 
*100µL of the spiking sample was added to 100µL of the serum samples. 
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Table 29. Precision and reproducibility for the measurement of serum folate concentrations in the 
common marmoset using the Immulite folate assay. Reprinted with permission.119 
Sample Number of 
repeats 
Mean  
(ng/ml) 
Standard Deviation 
(ng/ml) 
Coefficient of 
variation (%) 
Intra-assay variability 
Serum 1 5 13.8 0.5 3.7 
Serum 2 5 18.2 1.7 9.4 
Serum 3 5 9.7 0.5 5.4 
Serum 4 5 22.2 0.4 1.8 
 
Inter-assay variability 
Serum 5 5 13.9 0.8 6.0 
Serum 6 5 16.8 0.9 5.5 
Serum 7 5 9.6 0.4 3.7 
Serum 8 5 21.8 0.9 4.1 
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calculating the reference interval. Reasons for exclusion included weight loss (7), a diagnosis of 
Giardiasis or treatment for Giardia (6), loose stool (1), and a transient gastrointestinal upset (1).  
Due to lack of sufficient sample volume for down dilution, a final concentration was not 
determined for samples from some animals. A reference interval for serum cobalamin was 
established as 322 – 2,642 pg/mL using samples form 35 healthy marmosets. In order to achieve 
the final cobalamin concentrations, serum samples were run without any dilution (neat) for 18 
samples and in a 1:3 dilution for 17 marmosets samples, respectively.  
A reference interval for serum folate concentrations was established as 54.8 – 786.4 ng/mL 
using 37 samples form healthy marmosets. Twenty nine samples were run in 1:40 dilution, 5 in a 
1:20, 2 in a 1:100 dilutions, and 1 without any dilution to achieve the final concentration.  
6.3.3 Health comparisons 
Gender, dam, sire, birthplace, multiple births, litter size at weaning, obesity status, and age 
group were not significantly associated with either serum cobalamin or serum folate concentration 
(Table 30). Interestingly, serum folate concentrations were significantly different between the two 
centers (BMAC, SNPRC) where the samples had been collected (P=0.0108).  
Serum cobalamin concentrations were significantly different (P=0.0002) between the 
healthy marmosets (median (range): 1,020 pg/mL (281-2,390 pg/mL)) and the 14 marmosets with 
a previous history of gastrointestinal disease (median (range): 536 pg/mL (150-1,051 pg/mL)). 
However, there was no significant difference folate serum concentrations between the two groups 
(P=0.356). 
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Table 30. Table showing the different factors, the respective P values, and adjusted P values for 
serum cobalamin and folate concentrations. Reprinted with permission.119 
Factors  
Folate Cobalamin 
P value Adjusted P values P value Adjusted P values 
Source (SNPRC, 
BMAC) 0.001* 0.011* 0.289 2.603 
Sex  0.525 4.725 0.574 5.170 
Dam  0.088 0.794 0.128 1.150 
Sire 0.126 1.134 0.069 0.617 
Birthplace 0.092 0.825 0.066 0.594 
Multiple Births 0.080 0.716 0.263 2.363 
Weaned Litter Size 0.682 6.138 0.418 3.761 
Obesity Status 0.273 2.455 0.325 2.923 
Age Group 0.477 4.289 0.141 1.265 
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6.3.4 Repeated measurements of serum cobalamin and folate 
Repeated measurements of serum cobalamin and folate from the same animals were 
available from at least two different time points for 30 animals, with 8 animals having samples 
from 3 different time points, and 1 animal having samples from 4 different time points. Due to the 
lack of sufficient volume, cobalamin measurements could not be performed in 6 serum samples, 
and folate measurements could not be performed in 2 serum samples. In 23 animals, repeat serum 
samples for cobalamin concentration were available after a median of 120 days [minimum – 
maximum: 77 -165] of the first collection and results were not significantly different from baseline 
measurement (p= 0.726). In 8 animals, serum samples for cobalamin concentration measurements 
were available after a median of 223 days [minimum – maximum: 222 - 258] and were also not 
significantly different from baseline measurements (P= 0.547).  
In 26 animals, repeat serum samples for the measurement of folate concentration were 
available after a median of 123 days [minimum – maximum: 88 -165] of the first collection and 
results were not significantly different from the first measurement (P= 1). In 7 animals, serum 
samples for the measurement of folate concentration were available after a median of 223 days 
[minimum – maximum: 222 - 258] after baseline collection and were also not significantly 
different (P = 0.375).  
6.3.5 Serum cobalamin and folate concentrations in marmosets with CLE and gastrointestinal 
disease 
Serum cobalamin and folate concentrations and paired necropsy diagnosis was available 
for 38 marmosets from the NEPRC. Of these, 8 marmosets were healthy, 11 marmosets had CLE, 
and 18 marmosets died or were euthanized because of other diseases including: intestinal 
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adenocarcinoma (2), chronic nephritis / renal disease (15), hepatic lipidosis (4), pancreatitis (2), 
peritonitis (1), cholecystitis (4), steatohepatitis (1), chronic prostatitis (1), enteropathogenic E. coli 
(1), lymphoma and ulcerative enteritis (1). Median [minimum – maximum] serum cobalamin 
concentrations were 226 pg/mL [213- 627 pg/mL] in healthy marmosets, 225 pg/mL [149 – 514 
pg/mL] in marmosets with CLE, and 297 pg/mL [149 – 663 pg/mL] in marmosets with other 
diseases and serum cobalamin concentrations were not significantly different between the 3 groups 
(P= 0.148). Median [minimum – maximum] serum folate concentrations were median [minimum 
– maximum] 141 ng/mL [84- 230 ng/mL] in healthy marmosets, 68.6 ng/mL [18.3 – 226 ng/mL] 
in marmosets with CLE, and 203 ng/mL [28.3 – 327 ng/mL] in marmosets with other diseases 
respectively and serum folate concentrations were significantly different between the 3 groups (P= 
0.001). Furthermore, serum folate concentrations were significantly different between marmosets 
with CLE and those with other diseases (P= 0.008). 
Sensitivity and specificity for low serum cobalamin concentrations using a cutoff value of 
<322.0 pg/mL for the diagnosis CLE were 44.4% (95% CI; 21.5% to 69.2%) and 81.8% (95% CI: 
48.2% to 97.7%), respectively. Sensitivity and specificity for low serum folate concentrations 
using a cutoff value of <54.8 ng/mL for the diagnosis of CLE were 71.4% (95% CI: 29.0% to 
96.3%) and 73.9% (95% CI: 51.69% to 89.8%), respectively.  
Given that the other diseases, such as E.coli infection or intestinal carcinoma involved the 
gastrointestinal tract, an attempt was further made to classify the animals as healthy (n=8), those 
with diseases of the gastrointestinal tract (n=15), and those with no diseases of the gastrointestinal 
tract (n=15). Serum cobalamin concentrations were not significantly different between the 3 
groups (P= 0.484). However, serum folate concentrations were significantly different between the 
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3 groups (P= 0.040). Furthermore, serum folate concentrations were significantly different 
between marmosets with GI disease and those with extra-gastrointestinal diseases (P= 0.036). 
Sensitivity and specificity for a low serum cobalamin concentration using a <322.0 pg/mL cutoff 
value detection of GI disease were 57.9% (95% CI; 33.5% to 79.8%) and 63.6% (95% CI: 30.8% 
to 89.1%), respectively. Sensitivity and specificity for a low serum folate concentration using a 
<54.8 ng/mL as a cut off for gastrointestinal disease were 85.7% (95% CI: 42.1% to 99.6%) and 
60.9% (95% CI: 35.5% to 80.3%), respectively.  
6.3.6 Cross sections and longitudinal measurements of serum cobalamin and folate concentrations  
In a cross-sectional study serum cobalamin and folate concentrations were measured in 43 
animals from the NEPRC. Using a cobalamin concentration of <322.0 pg/mL as a cut-off value 
for a low cobalamin, 15/43 animals had a decreased serum cobalamin concentration. Using a serum 
folate concentration of <54.8 ng/mL as a cut-off value for a low folate, 2/43 animals had a 
decreased serum folate concentration. 
In a longitudinal study, serum cobalamin and folate concentrations were measured in 4 
animals from the NEPRC over a period of several years. Final necropsy diagnosis, cobalamin, 
and folate concentrations were also available for review (Table 31). Serum cobalamin and folate 
concentrations for these 4 animals are shown in Figures 8 and 9, respectively.  
 
6.4 Discussion 
Analytical validation of an assay is neccessary when immunoassays are used for the first 
time in any species. Species specific reference intervals also need to be generated and often a the 
dilution of samples to bring them into the working range of an assay is required.146 We performed  
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Table 31.  Serum cobalamin and serum folate concentrations over time as well as necropsy 
findings in the 4 marmosets from the NEPRC (longitudinal study). Reprinted with permission.119 
M
ar
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     Necropsy findings 
 
 
Days*  
Cobalamin 
concentration** 
(pg/mL) 
Folate 
concentration*** 
(ng/mL) 
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n
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M
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1 CLE, nephritis 1775 >1001 882 >1001 156 104 772 
2 CLE, cholecystitis, and 
nephritis 
3514 391 391 >1001 106 15.9 529 
3 Pancreatitis, hepatic 
amyloidosis, and 
cholecystitis 
2283 224 149 362 158.5 103 300 
4 No significant findings 2654 <149 <14
9 
213 250 33.1 786 
CLE = chronic lymphocytic enteritis 
* Days between the first and last sample available for testing. 
** See Figure 8 for display of serum cobalamin concentrations over time 
*** See Figure 9 for display of serum folate concentrations over time 
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Figure 8. Serum cobalamin concentrations in 4 marmosets at the NEPRC over a period of several 
years. Reprinted with permission.119 
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Figure 9. Serum folate concentrations in 4 marmosets at the NEPRC over a period of several 
years. Reprinted with permission.119 
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a partial analytical validation of commercially available assays for the measurement of serum 
cobalamin and folate concentrations in humans for use in the common marmoset. The majority of 
the validation study was performed using pooled serum samples because of the lack of sufficient 
sample volumes from using samples from individual marmosets. This makes the detection of a 
possible matrix effect difficult. However, we showed that the Immulite assay for cobalamin and 
folate measurement is linear, accurate, precise, and reproducible for use with serum samples from 
the common marmosets. In the assessment of linearity by manual two-fold dilution, the samples 
chosen for cobalamin and folate were in the lower end of the working range of the assay, hence 
the increased O/E ratios. However, when samples with higher concentrations were diluted using 
the dilution function available within the Immulite, their CV% were within the accepted value of 
<30% for immunoassays,41 and very close to the stringent criteria of <20%,122 with only one value 
being 20.6%.  
The use of banked samples did not affect the concentration measurements made in this 
study. At least from our limited data set it would appear that serum cobalamin and folate 
concentrations are relatively stable when serum samples are stored at -80oC for up to 7 years.  
The reference interval for cobalamin established in the common marmoset (322 – 2,642 pg/mL) is 
comparable to that reported in pig-tailed macaques (961 to 2,000 pg/mL) and rhesus macaques 
(727 to 2,000 pg/mL), using the same assay.65 Also, in vervet monkeys (Cercopithecus aethiops) 
using two different radioimmunoassays, plasma vitamin B12 concentrations have been reported in 
a similar interval; 1,545 ±451 pg/mL and 1,396 ± 450 pg/mL.162 
Serum folate concentrations have been reported in the Rhesus macaque using a 
microbiological assay using L. casei 103 for measurement and in the plasma of vervet monkeys 
using two immunoassays and were 15.0 ± 2.4 ng/ml , 10.2 ± 3.7 ng/mL , and 8.2 ± 2.2 ng/mL, 
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respectively. This is very different from the reference interval established in the common 
marmoset in this study and is probably related to the methodology employed. A dietary component 
cannot be ruled out as New World primate diets contain a folate supplement and the folate 
concentration seen in our study is significantly higher than what is observed in other monogastric 
species. 
Serum cobalamin concentrations in marmosets were not significantly different between the 
two primate centers (SNPRC and BMAC). It is possible that cobalamin concentrations might have 
been more diagnostic for CLE if the marmoset diets were not supplemented. In the wild, insects 
and small mammals serve as sources of cobalamin and comparing cobalamin concentrations 
between marmosets in the wild and those in primate research colonies may provide additional 
insights into the role of cobalamin and CLE.  
However, serum folate concentrations were significantly different between the two centers. 
Marmosets from the SNPRC did have higher serum folate concentrations than those at the BMAC. 
This could be attributed to three possible reasons, a dietary component, a diet treatment 
component, or differences in the gut microbiota. Marmosets at the BMAC were fed a purified diet 
(#TD.07148 Marmoset Diet, Harlan Teklad Madison, WI), and a primate enrichment mixture 
consisting of nuts, seeds, and dried fruit from the same manufacturer. However, both these diet 
components are also irradiated at the manufacturing plant. Marmosets at the SNPRC are on two 
diets, a commercial New World primate diet (Mazuri diet (AVP Callitrichid 5LK6) and also on 
the same purified diet (without irradiation) used at the BMAC. Diet for marmosets at the SNPRC 
also included daily food enrichment, such as yogurt, fruits, cheerios, etc. which are also good 
additional sources of folate.40 Supplementation of folate in the diet does lead to increased plasma 
concentrations in other primate species.162 Irradiation has been reported to decrease folic acid 
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concentrations by 20-30% in certain foods162 and it is not known if irradiation had a similar effect 
here.  Folate is mainly synthesized by jejunal bacteria77 and differences in the fecal microbiome 
have been reported between the marmosets of these two colonies,130 and this could be another 
reason for changes in serum folate concentrations between the two centers. Given these 
observations, marmoset colony specific reference intervals for serum folate concentrations perhaps 
may be more appropriate specifically for colony monitoring purposes for gastrointestinal health.  
While folate concentrations were not significantly different between marmosets with a 
history of gastrointestinal disease and those without such a history, serum cobalamin concentration 
was. However, only 3/14 of the marmosets (21.4%) had serum cobalamin concentrations, lower 
than the established reference interval. In a recent study,65 looking at macaques with chronic 
diarrhea, 5/6 pigtail macaques had decreased serum cobalamin concentrations, but all 6 rhesus 
macaques with chronic diarrhea had normal cobalamin concentrations. Cobalamin concentrations 
are reported to be low in some humans with IBD,10 and dogs with chronic enteropathy.14 A dietary 
cause for a decreased serum cobalamin concentration is unlikely in these marmosets fed a 
commercial diet.65 Rhesus macaques fed cobalamin deficient diets were asymptomatic for 12-18 
months despite severely decreased serum cobalamin concentrations.73 Therefore, absence of 
clinical signs are not sufficient to assume normal serum cobalamin concentrations. Other reasons 
for low cobalamin concentrations include genetic defects, changes in the gut microbiota,140 
hyperthyroidism,34 exocrine pancreatic insufficiency, 141 lymphoma,141 ageing,167 and metabolic 
causes.145  
The diagnostic utility of decreased serum concentrations of cobalamin and/or folate for the 
diagnosis of CLE or gastrointestinal disease in the common marmoset, were suboptimal; lower 
serum folate concentrations were moderately sensitive (>70%) for gastrointestinal disease or CLE, 
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and lower cobalamin concentrations were specific (>80%) for CLE. This makes their utility in the 
diagnosis of CLE or occult gastrointestinal disease limited. Nonetheless, it may serve as a 
screening test as no ante-mortem tests are currently available. However, it does raise questions 
regarding the value of supplementation of these vitamins in animals with CLE or gastrointestinal 
disease. False positive and false negative rates for detecting cobalamin deficiency using 
commercial assays are as high as 50% in human beings.145 This is because these assays measure 
intrinsic factor binding of cobalamin, and measures both serum holohaptocorrin and serum 
holotranscobalamin and can mask true deficiency or falsely imply a deficient state. For this reason, 
in human beings, a low cobalamin concentration triggers the measurement of a functional 
biomarker such as methylmalonic acid and/or homocysteine, which are considered 
confirmatory.29,42 Studies in dogs with chronic gastrointestinal disease have also shown that only 
a subset of dogs do have decreased cobalamin concentrations, and only a subset of these dogs have 
increased serum methylmalonic acid concentrations, suggesting a deficiency of cobalamin at the 
cellular level.14,16 Thus, additional studies are warranted in the common marmoset, to evaluate 
cobalamin and folate deficiencies at the cellular level. 
Lower folate concentrations in marmosets with CLE and gastrointestinal disease are 
interesting as marmosets raised on a folate restricted diet developed clinical signs that terminated 
fatally in 59 to 136 days.43 These clinical signs observed included anorexia, weight loss, diarrhea, 
alopecia, ulceration of the oral and intestinal mucosa, anemia, leucopenia and granulocytopenia, 
some of which have been reported with marmosets with CLE. Serum folate measurements, when 
compared to cobalamin concentrations, are adequate for the diagnosis of folate deficiency and red 
blood cell folate measurement are only indicated rarely.48 
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The fact that serum concentrations of cobalamin and folate from the marmosets from the 
same colony measured 120 and 220 days apart did not change significantly would suggest that the 
concentrations are stable over relatively long periods of time. The data from the 4 animals from 
the NEPRC show that normal marmosets can have very low cobalamin concentrations for long 
periods of time without any clinical signs (marmoset 4), and marmosets with CLE can have normal 
serum cobalamin and folate concentrations (marmoset 1). It is noteworthy, that in one animal with 
CLE, cobalamin and folate concentrations (marmoset 2) did decrease in over 600 days. It remains 
unknown if there are subsets of marmosets with CLE based on their response to diets, antibiotics, 
or immunosuppressive (steroids) drugs, as has been described for other species, such as the dog.70  
The major limitation of this study was that it was based on archived samples. Blood volumes from 
the marmosets were a limiting factor and pooled samples were used for the validation, which was 
not ideal as it did not allow us to fully assess the presence of any matrix effects. Also, a relatively 
small number of animals were used to establish the reference intervals. In an ideal scenario serum 
samples from at least 120 marmosets would have been used to establish the reference intervals as 
recommended by the International Federation of Clinical Chemistry (IFCC).   
To conclude, we validated a commercially available assay for the measurement of serum 
cobalamin and folate for use in humans in the common marmoset. We also established reference 
intervals for serum cobalamin and folate concentrations in the common marmoset. The difference 
in serum folate concentration between centers suggests that facility specific reference intervals 
may be more appropriate for this analyte. Low serum cobalamin and folate concentrations were 
observed in some common marmosets with gastrointestinal disease, and chronic lymphocytic 
enteritis. However, additional studies are necessary to further elucidate the utility of these 
measurements in the common marmoset.   
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CHAPTER VII 
FECAL N-METHYLHISTAMINE CONCENTRATIONS IN THE COMMON MARMOSET 
(CALLITHRIX JACCHUS). ∞∞ 
 
7.1 Introduction 
The common marmoset (Callithrix jacchus) is a New World monkey employed in 
biomedical research since the early 1960’s. Its popularity has increased over the years,1 particularly 
because of their small size, reduced cost for maintenance compared to larger primates, easy 
husbandry, rapid reproductive turnover, and decreased susceptibility to certain human pathogens.90 
Inflammatory diseases of the gastrointestinal tract, particularly of the large intestine, have been 
described in marmosets since their initial use in biomedical research.32,38,158 Inflammatory bowel 
disease (IBD), particularly chronic lymphocytic enteritis (CLE), has been a consistent finding in 
C. jacchus colonies with prevalence rates as high as 60.5% of all marmosets used as controls in 
various studies at one center.88 No specific etiology has been identified; however many etiological 
factors such as, gluten sensitivity, dietary protein deficiency, and the pancreatic spirurid nematode 
(Trichospirura leptostoma) have been suspected. Clinically, failure to thrive in juveniles, or weight 
loss in adults, with or without diarrhea are observed. Diffuse to segmental lymphocytic enteritis is 
seen on histology.88  
Currently an antemortem diagnosis is made based on clinical signs, a history of weight 
loss, and a decreased serum albumin concentration.11 No proven effective treatment exists and a 
final diagnosis is usually112 made only at necropsy. Newer markers like fecal calprotectin,108 fecal  
∞∞Submitted to Comparative Medicine. Parambeth JC, López RF, Lopes R, Keyser S, J  Lidbury 
JA, Suchodolski JS, Steiner JM. Fecal N-methylhistamine concentrations in the common 
marmoset (Callithrix jacchus). 
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α1-PI, serum matrix metalloproteinases,171 serum IgA antibodies to gliadin and related proteins84 
are being investigated and may serve as markers in the future. Treatment with steroids,115 or 
tranexamic acid 172 may also hold some promise in the future.   
Mast cells have been described in the gastrointestinal tracts of dogs50 and humans,127 and 
have been investigated in chronic enteropathies of dogs6,13 and inflammatory bowel disease111 in 
humans.  
The role of mast cells has not been determined in marmoset CLE. Mast cells can be missed 
on routine hematoxylin-eosin staining. Their detection requires either special staining with 
toluidine blue or immunohistochemistry for mast cell tryptase.6,13 Markers of mast cell activation 
rather than their absolute numbers seen on histology have also been suggested as a better method 
to measure their activity. Histamine is primarily stored in the mast cells and serves as marker of 
mast cell degranulation. Rapid metabolism of released histamine leads to N-methylhistamine 
(NMH) and imidazole acetaldehyde.153 Fecal concentrations of NMH were found to be increased 
in a subset of dogs with chronic enteropathies, suggesting that mast cell mediated inflammation 
plays a pathogenic role.6,13   
We hypothesize that fecal NMH concentrations are increased in marmosets with chronic 
lymphocytic enteritis and this could be used as a marker of intestinal inflammation in these 
patients. Therefore, the aim of this study was to measure NMH concentrations in fecal samples 
collected from healthy marmosets, establish a reference interval, and compare the concentrations 
from healthy marmosets to marmosets with chronic lymphocytic enteritis.  
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7.2 Materials and methods 
7.2.1 Sample collection  
Samples were collected from a total of 30 healthy marmosets maintained at the Southwest 
National Primate Research Center (SNPRC), Texas Biomedical Research Institute, San Antonio, 
Texas and the Barshop Marmoset Aging Center (BMAC), The University of Texas Health Science 
Center, San Antonio, Texas. Collection of fecal samples was approved from both institutional 
IUCAC (AUP # 1259CJ for Texas Biomed, and 06120X for UTHSCSA). Three consecutive, 
naturally passed fecal samples were collected from each marmoset in a fecal collection tube (Fecal 
collection tube (101 × 16.5 mm; with spatula), Sarstedt AG&Co., Nümbrecht, Germany) and 
frozen immediately. Marmosets sampled did not have had any clinical signs of gastrointestinal 
disease and were not part of any research studies during the sampling process.   
Single time point fecal samples were also collected per rectally from 16 marmosets at 
necropsy. These marmosets died or were euthanized at the New England Primate Research Center 
(NEPRC), Southborough, MA; these samples were frozen immediately after collection. The 
necropsy and sample banking were part of routine colony management procedures and included 
sick and healthy marmosets. The investigators were blinded to the final postmortem diagnosis of 
these animals when the assays were run. Gastrointestinal tissue samples where available were also 
obtained from these animals for additional staining for mast cells.  
All the fecal samples were shipped to the Gastrointestinal Laboratory at Texas A&M 
University overnight with dry ice. Fecal samples were stored at -80oC and extracted later. Fecal 
extracts were stored at -80oC until NMH analysis. 
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7.2.2 Preparation of fecal samples.  
A fecal NMH extraction protocol similar to that previously described in domestic dogs 133 
was used. Briefly, fecal samples were extracted in 1:5 phosphate buffered saline (BupH™ 
Phosphate buffered Saline, Thermo Scientific, Rockford, IL)-new born calf serum buffer 
(Newborn Calf Serum, Sigma-Aldrich Co., St. Louis, MO), followed by vigorous shaking in an 
automated shaker for 20 minutes. The fecal tubes were then centrifuged at 3,000g for 20 minutes 
and filtered using a serum filter (Fisherbrand® serum filter system, Fisher Scientific Inc., 
Pittsburgh, PA). The resultant supernatant, (fecal extract) was used for the assay.  
 
7.2.3 N-methylhistamine assay 
N-methylhistamine in the fecal extracts was measured using stable isotope dilution gas 
chromatography/mass spectrometry (GC/MS) as previously described for those from domestic 
dogs.133  Briefly, 50 pg of trideuterated NMH (CDN Isotopes, Pointe Claire, QC, Canada) was 
added to 200µL of fecal extract as an internal standard. Then 200µL of borate buffer (pH 9, 10mM) 
was added. The sample was vortexed and then applied on a solid phase silica extraction column 
(Sep-Pak cartridge, Waters, Milford, Massachusetts). The columns were washed with changes of 
chromatography grade water and then the sample was eluted with 0.1N HCl acidified methanol 
(VWR International, West Chester, Pennsylvania). The eluted samples were evaporated to dryness 
using nitrogen on a heating block. The dried sample was reconstituted with 300 μL of 20% 
methanol in chloroform (VWR International, West Chester, Pennsylvania), before application to 
the second solid phase silica extraction column. The column was washed with 150µl of 20% 
methanol in chloroform (VWR International, West Chester, Pennsylvania). The sample was eluted 
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with four one mL volumes of methanol:chloroform:ammonium hydroxide (25:25:1, v/v) and dried 
as before.  Derivitization was achieved by adding 200µl ethyl acetate (Sigma-Aldrich Corp., St. 
Louis, MO, USA), 40µl pyridine (Thermo Fisher Scientific, 168 Third Avenue, Waltham, 
Massachusetts), and 100µl pentafluoropropionic anhydride (Sigma-Aldrich Corp., St. Louis, MO, 
USA), to the sample and incubating at ~64oC for 40 minutes. The samples were evaporated to 
complete dryness as before. In the next partitioning step, 500µL of 0.5 M Tris buffer was added to 
each sample, followed by 1.5 ml of hexane (Sigma-Aldrich Corp., St. Louis, MO, USA). The 
samples were vortexed for 1 minute and centrifuged at 574 g for one minute. The hexane top layer 
was collected and another 1.5 mL of hexane was added to each sample and the process was 
repeated. The two hexane fractions were combined and evaporated to dryness Before transferring 
to a GC/MS autosampler vial, the residue was reconstituted with 30 µL of ethyl acetate and 
vortexed. The GC/MS analysis was performed using the Agilent 690N GC and 5975C MSD with 
a dimethylpolysiloxance capillary column, all other conditions (temperature, carrier gas, gradient, 
and pressure) used were similar to what has been described in the earlier fecal NMH assay in dogs. 
A standard curve from 0 to 5,000 pg/μL was run prior to each run to evaluate assay performance. 
NMH and deuterated isotopes were quantified by use of the ions at an m/z of 417 and 420, 
respectively. Fecal concentrations of NMH were back calculated for the wet weight of the sample 
and reported in ng/g feces.  
 
7.2.4 Partial validation 
Since the assay has not been validated for use in the common marmoset, a partial validation 
to assess linearity and accuracy was done. Linearity was determined by calculating observed-to-
expected (O/E) ratios for three pooled (due to lack of sufficient volume) fecal extracts serially 
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diluted 1:2 and 1:4. Accuracy was measured by calculating O/E ratios for three pooled fecal 
extracts that were spiked with three different NMH concentrations (125 pg/µL, 500 pg/µL, and 
1250 pg/µL; equivalent to assay standards).  
 
7.2.5 Establishment of the reference interval in healthy marmosets 
Single time point, 3-day mean and 3-day maximum concentrations for fecal NMH were 
measured and used to establish the reference interval for healthy marmosets. The coefficient of 
variation was calculated between the three-day collections. A reference interval was established 
by calculating the upper 95th percentiles of the single time point, the three-day mean, and the three-
day maximum fecal NMH concentrations. For the single time point the sample from the 1st day of 
collection was utilized.   
 
7.2.6 Necropsy results & fecal NMH concentrations 
Full necropsy data, including gross findings, microscopic findings, and summary from the 
pathologist was obtained from 16 marmosets from the NEPRC who had fecal samples collected 
and analyzed. Fecal NMH concentrations were correlated to the postmortem findings. 
 
7.2.7 Histology and mast cell counts 
Gastrointestinal (stomach, small intestine and large intestine) sections collected at 
necropsy were obtained from the NEPRC where available and were stained with routine 
hematoxylin and eosin and toluidine blue using routine protocols. Sections stained with H&E were 
not revaluated but were assessed to ensure that they were full thickness sections and contained 
mucosa, submucosa and muscularis propria. Only full thickness sections were considered for the 
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toluidine blue staining. Sections stained with toluidine blue were evaluated by one board-certified 
anatomic pathologist (Lopez) and mast cells were counted in 4 high-power fields (400×) per tissue.  
 
7.2.8 Statistical analysis 
Statistical computation was performed with a commercial software package GraphPad 
PRISM5.0 (GraphPad software, Inc. La Jolla, CA) and statistical significance was set at P<0.05. 
In addition, the coefficient of variation (%CV = [standard deviation/mean] × 100) was used to 
determine the variability in the fecal concentrations of NMH from the three-day samples. 
Sensitivity and specificity will be calculated using an online calculator 
(https://www.medcalc.org/calc/diagnostic_test.php). 
 
7.3 Results 
For the partial validation of the assay, one of the three samples failed to go through the 
column as expected and had to be excluded. For assessment of the linearity, the O/E % was 
137.1%, and 124.6% for one sample at 1:2, and 1:4 , respectively, and 101.4%, and 76.3% for the 
other sample at the same dilutions. Accuracy O/E % for the two fecal extracts that were spiked 
with three different NMH concentrations (125 pg/µL, 500 pg/µL, and 1250 pg/µL; equivalent to 
assay standards) were 84.5%, 85.2%, and 76.1% for one sample, and 74.1%, 80.7%, and 72.8% 
for the other.  
Thirty healthy marmosets were used to establish the reference interval. Of these, 16 animals 
were from the SNPRC, and 14 were from the BMAC. The concentrations of NMH detected in 
fecal extracts ranged from undetectable to 216.1µg/g of feces. Using the upper 95th percentile the 
reference intervals were determined to be ≤ 118.2ng/g of feces for a single fecal sample, ≤ 
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121.7ng/g of feces for the 3-day mean, and ≤167.5ng/g for the 3-day maximum. The median inter-
day coefficient of variation from each subject was 42.2% [minimum-maximum: 7.1- 141.4%].  
Only 14 of the 16 single time point fecal samples collected from marmosets undergoing 
postmortem examination  at the NEPRC were available for analysis. The particulars of the animals 
and the fecal NMH concentrations are shown in Table 32. Conditions included CLE (7), healthy 
controls (2), renal failure (2), lymphoma with ulcerative enteritis (1), enteropathogenic E. Coli (1), 
and adenocarcinoma (1). Diagnosis of CLE was established histologically. Seven of the 14 animals  
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Table 32. Summary of data in 14 marmosets from the NEPRC with fecal NMH concentrations. Reprinted with permission.118 
Marmoset 
Number Sex 
Body 
Weight 
(g) 
Age in 
days  
Cause of 
death Clinical history  
Post mortem diagnosis 
based on gross and 
microscopic examination 
Fecal 
NMH 
(µg/g) 
1 Female 415.7 1243 Euthanized 
Control for 
clinical study 
Normal animal 18.0 
2 Male 456.8 1400 Euthanized 
Control for 
clinical study 
Normal animal 35.0 
3 Female 336.7 3757 Euthanized 
Suspected CLE, 
wasting and poor 
health 
Chronic lymphocytic 
enteritis 
994.8 
4 Male 398.9 
Not 
available 
Spontaneous 
found dead 
None  
Chronic lymphocytic 
enteritis 
396.6 
5 Male 292.8 5372 Euthanized 
Suspect mass in 
abdomen 
Chronic lymphocytic 
enteritis 
219.5 
6 Female 485.5 
Not 
available 
Euthanized 
Diabetic with 
lymphocytosis 
Chronic lymphocytic 
enteritis 
228.6 
7 Female 353.1 
Not 
available 
Euthanized 
Suspect mass in 
abdomen 
Chronic lymphocytic 
enteritis 
106.7 
8 Female 305.6 2346 Euthanized 
Suspected CLE, 
wasting and poor 
health 
Lymphoma &  Ulcerative 
enteritis 
1540.0 
9 Female 307.0 5170 Euthanized 
Suspect E Coli 
infection 
Enteropathogenic E. Coli 24.4 
10 Female 302.0 3796 Euthanized Doing poorly Adenocarcinoma  111.4 
11 Male 456.0 3654 Euthanized Chronic diarrhea 
Chronic lymphocytic 
enteritis 
256.7 
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Table 32. Continued 
Marmoset 
Number Sex 
Body 
Weight 
(g) 
Age in 
days  
Cause of 
death Clinical history  
Post mortem diagnosis based 
on gross and microscopic 
examination 
Fecal NMH 
(µg/g) 
 
12 Female 400.5 3838 Euthanized Chronic diarrhea 
Chronic lymphocytic 
enteritis 
236.5 
13 Male 272.9 6304 Euthanized Weight loss Renal failure 83.4 
14 Male 357 4667 Euthanized Renal failure Renal failure 23.8 
 
NMH – N-methyl histamine 
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had fecal NMH concentrations greater than the upper limit of the reference interval, and 6/7 of 
these had CLE. For diagnosis of CLE from a single fecal sample using a diagnostic cutoff of ≤ 
118.2 ng/g the sensitivity of this assay is 86% (95% confidence interval: 42% to 100%), and the 
specificity of 86% (Range 42% to 100%; 95% confidence interval).  
Of these 14 marmosets, extra tissue was only available for 6 for mast cell counting. Their 
details and the counts are shown in Table 33. Given the small number of animals, no statistical 
analysis was done.  
 
7.4 Discussion 
CLE is a common disease in marmoset colonies. A minimally invasive test to detect CLE 
would be beneficial in the common marmoset. Fecal NMH concentrations were increased in 7/8 
common marmosets with CLE suggesting that this test may have diagnostic utility.  
Based on the limited number of samples tested, the linearity and the accuracy of NMH 
GC/MS assay seems adequate for the assessment of marmoset fecal samples. The linearity and 
accuracy seem comparable to when this assay was used for measurement of NMH in dog fecal 
samples (dilutional parallelism O/E: 88.6% to 115.0%; mean spiking recovery O/E: 104.2%).133  
The concentrations of NMH detected in fecal extracts ranged from undetectable to 
216.1µg/g of feces. Undetectable NMH concentrations have also been reported in the dog.133 The 
reference intervals established for the common marmoset fecal samples are comparable to canine 
reference intervals of ≤191 ng/g feces and ≤334 ng/g feces, for the 3-day mean and maximum fecal 
NMH concentrations, respectively.13 To account for variations in fecal NMH concentrations, 3-
day mean or 3-day maximum concentrations have been used in other studies,13 and may also be 
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Table 33. Distribution of mast cells in the gastrointestinal tract of 6 marmosets from the NEPRC. 
Reprinted with permission.118 
 
Marmoset 
Number  
Necropsy 
diagnosis Mast cells in four 20x fields from each slide 
    Stomach Small Intestine 
Large 
Intestine 
      Duodenum Jejenum Ileum 
Cecum/ 
Colon 
1 Normal control 42 14 4,14 NA 7,3,6a 
2 Normal control NA 11 27,46 7,21b 3,21b 
4 
Chronic 
lymphocytic 
enteritis 169 12 51,21 93 38,0,23 
5 
Chronic 
lymphocytic 
enteritis NA 23 110,78 109 47,69 
10 Adenocarcinoma  NA NA 26,38 NA 5,21 
13 Renal failure 33 NA 43 NA 46, 57, 82 
 
NA= Not available; numbers separated by commas suggest multiple slides were available.  
 
Superscripts next to numbers indicated less than 4 fields were counted; a = 3 fields, b = 2 fields 
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more appropriate in the common marmoset given the intra-individual variation observed in this 
study.  
The observed increases in fecal NMH concentrations for marmosets with CLE compared 
to controls and estimated diagnostic sensitivity and specificity suggest that this may have utility 
for the non-invasive diagnosis of this disease in marmosets. However, further studies with a larger 
number of animals are needed. Currently, the gold standard for diagnosis is post mortem 
examination and it is difficult to establish a definitive diagnosis ante-mortem. Therefore, a non-
invasive test may allow earlier and more accurate diagnosis of this common disease. Fecal NMH 
was normal in one marmoset with CLE, this could represent a separate subtype of the disease, 
severity, issues with sample handling, or because of the intra-individual variation observed in the 
study. Increased concentration of fecal NMH was also observed in a case of lymphoma and 
ulcerative enteritis and which was unexpected. Increased mast cell activation currently known as 
‘mast cell activation syndrome’ has been reported with chronic inflammatory or neoplastic 
disorders3. It is uncertain what leads to this increase and unfortunately no histological sections 
were available for evaluation of mast cells numbers in the gastrointestinal tract of these animals. 
Previously fecal NMH concentrations were also shown to be increased in some dogs with chronic 
enteropathies.6,13 These studies also showed that fecal NMH was increased more in dogs with 
moderate intestinal inflammation, and only sometimes in dogs with mild inflammation. 
Canine and human studies have used urine NMH to creatinine ratios as indicators of active 
disease,6,13,163 or endoscopically diagnosed disease.166 In our study, feces was used because the 
samples were already available, and were easier to collect. Some authors also believe that 
histamine concentrations in stool do not reflect a person's systemic burden but luminal active 
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histamine,69 and hence feces may be a better marker of mast cell activation in CLE, and this is 
another reason why fecal samples were used rather than urine for our study. 
To the best of our knowledge mast cells have not been described in the marmoset 
gastrointestinal tract. Previous studies evaluating mucosal mast cell numbers in dogs76 and humans 
have reported mixed results. Staining techniques particularly employing toluidine blue may not be 
accurate as it only stains intact mast cell granules, whereas immunohistochemical stains targeting 
mast cell tryptase also react with residual enzymes from degranulated cells. Metachromatic stains 
are significantly cheaper than immunohistochemical staining and that is the reason we decided to 
pursue this in our study. A patchy distribution of mast cells throughout the gastrointestinal tract, 
non-representative biopsies, or ongoing degranulation of mast cells resulting in their depletion 
have also been reported as potential causes why mast cell counts may not be true representation of 
the disease process.13 These could potentially explain the variation seen in the mast cell counts in 
the same location from the same marmoset in our study. In one healthy animal, mast cells reported 
in the colon were 3 and 21, and in a marmoset with CLE, they were 38, 0, and 23, raising concerns 
for a patchy distribution. However, no conclusions can be made, based on these findings, given 
the small number of animals.  
Given that all the necropsy samples were from the same institution (NEPRC), and primate 
necropsies and histology are a common practice performed by boarded anatomic pathologists, no 
attempts were made to reevaluate the diagnosis of CLE in these samples. A report from a study in 
dogs6 suggested that increased numbers of intestinal mast cells were seen in dogs responding to 
diet and/or antimicrobial therapy compared to immunosuppressive medications. This would have 
been valuable information if any such increases were detected in our study as it would help to 
guide treatment in the marmosets, unfortunately this could not be done due to low sample numbers. 
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The major limitation in this study was the small sample size (n=30) for establishing the 
reference interval, as well as the small number of animals (n=14) that underwent a necropsy and 
could subsequently be used to estimate diagnostic accuracy. No laboratory data were available to 
see if these animals also had low albumin concentrations or were anemic as described in previous 
studies. Given the small number of samples (n=6) available for specific staining of mast cell, no 
association between presence of mast cells and NMH concentrations could be demonstrated. 
Optimum fecal sample handling and storage conditions were also not assessed in this study. Since 
fecal samples were collected in the necropsied animals after death, it is unknown how much that 
could have an effect on the fecal NMH concentrations.  
It is also possible that marmosets with increased fecal NMH concentrations and CLE 
demonstrated on histology were terminally ill and hence euthanized. Hence, the utility of fecal 
NMH in healthy colonies, or as an early marker of CLE remains uncertain.  
Even with the given the limitations, the study however does suggest that common 
marmosets with chronic lymphocytic enteritis may have increased fecal NMH concentrations. 
Further studies in a larger number of common marmosets are warranted to better evaluate the role 
that mast cells play in chronic lymphocytic enteritis and to fully evaluate the utility of this test.  
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CHAPTER VIII 
SUMMARY AND CONCLUSIONS 
 
The common marmoset (Callithrix jacchus) is a New World primate that is being used 
extensively in biomedical research. Chronic diseases of the gastrointestinal tract, particularly 
chronic lymphocytic enteritis (CLE), is frequently observed in captive common marmoset research 
colonies. CLE is characterized by weight loss or a failure to thrive, hypoproteinemia, and anemia 
in affected marmosets and is often associated with death. To date, no single etiology has been 
identified and a multifactorial pathogenesis has been hypothesized. Ante-mortem diagnosis is 
challenging, as it requires ruling out other causes of gastrointestinal disease and other chronic 
diseases that maybe associated with similar clinical signs. A definitive diagnosis is made by 
confirmation of intestinal inflammation upon histopathology, which is often achieved during 
necropsy. Lesions are also observed in other organs such as the pancreas, liver, kidneys, and others. 
CLE is highly prevalent in research colonies, with a prevalence reaching as high as 60% in some 
colonies. Though recent reports suggest that the disease presentation is changing, CLE still poses 
a challenge for biomedical research using the common marmoset. Early identification of 
marmosets predisposed to CLE or those in the early stages of disease would help researchers using 
marmosets by facilitating their exclusion, particularly from long-term projects such as aging 
studies.11  
To date, no single serum or fecal biomarker evaluated has proven useful in the diagnosis 
of CLE in marmosets. Also, as no etiology has been identified, no effective treatment exists. The 
hypoalbuminemia associated with CLE in marmosets is presumed to be from enteric protein loss 
due to intestinal inflammation. Fecal concentrations of alpha1-proteinase inhibitor (α1-PI) have 
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been used to diagnose enteric protein loss in humans, dogs, and cats with gastrointestinal disease. 
However, immunoassays for the measurement of α1-PI  in feces are species specific and no cross-
immunoreactivity was observed evaluating marmoset serum in human, cat, or dog assays. Alpha1-
PI has not been previously studied in marmosets with CLE. Thus, this study was to determine if 
α1-PI is clinically useful as a biomarker of enteric protein loss and as a marker of intestinal 
inflammation in the common marmoset. Other serum and fecal markers of intestinal inflammation 
such as serum cobalamin and folate concentrations and fecal N-methyl histamine were also 
evaluated. 
 
8.1 Summary  
As a prelude to immunoassay development marmoset α1-PI was purified. Marmoset serum 
was used to purify α1-PI using immunoaffinity chromatography and ceramic hydroxyapatite 
chromatography. Partial characterization was achieved by determination of molecular weight (54 
kDa), relative molecular mass (51,677), and isoelectric point (4.8-5.4). Protein identity was 
confirmed with peptide mass fingerprinting and N-terminal amino acid sequencing 
(EDPQGDAAQKMDTSHH). Inhibitory enzyme activity of marmoset α1-PI for trypsin, 
chymotrypsin, and elastase was determined. The overall yield of marmoset α1-PI from serum was 
12% using this method. Purified marmoset α1-PI has structural and biochemical characteristics 
similar to those reported for α1-PI in other species. Polyclonal antibodies were raised in New 
Zealand white rabbits by inoculation of purified marmoset α1-PI using a commercial antibody 
production service. The specificity of the antibodies raised was confirmed by using a Western blot. 
Cross-reactivity of polyclonal antibody sera raised were tested against serum from several other 
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species using radial double immunodiffusion. Cross-immunoreactivity was only observed with 
serum from the Geoffrey’s marmoset. 
Pure marmoset α1-PI was labelled with radioactive iodine (125I) to generate a tracer.  A 
competitive double antibody radioimmunoassay (RIA) for the measurement of serum and fecal 
concentrations of marmoset α1-PI was successfully set up. The established RIA was analytically 
validated by determination of sensitivity, working range, dilutional parallelism, spiking recovery, 
and intra- and interassay variability and was found to be sensitive, linear, accurate, precise, and 
reproducible for the quantification of mα1-PI concentrations in serum and fecal extracts. A 
reference interval for mα1-PI concentrations in serum and feces was established in healthy 
marmosets.  
The use of a radiolabel [125I] in radioimmunoassay is a major drawback of 
radioimmunoassays, and with the short shelf life of the tracer,53 enzyme immunoassays might be 
preferable. Hence, a sandwich enzyme-linked immunosorbent assay (ELISA) for the measurement 
of α1-PI concentrations in serum and fecal extracts from the common marmoset was developed. 
Analytical validation of the ELISA was achieved by determining the lower limit of detection, 
linearity, accuracy, precision, and reproducibility. The ELISA was linear, accurate, precise, and 
reproducible for quantification of marmoset α1-PI concentrations in serum and fecal extracts, 
however, with limited linearity and accuracy for spiking recovery of fecal samples. Reference 
intervals for serum and fecal α1-PI concentrations in the common marmoset were 
established.Given the limited linearity and accuracy for measuring α1-PI concentrations in fecal 
extracts when using the ELISA, concentrations of α1-PI measured in the same fecal extract on both 
assays were compared using a Bland–Altman plot. Given the proportional bias identified between 
the RIA and the ELISA, the RIA was used for clinical validation. Fecal α1-PI concentrations were 
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determined from fecal samples collected at necropsy from healthy marmosets, those with CLE, 
and those with other diseases. This study showed that fecal α1-PI concentrations are not elevated 
in common marmosets with CLE. Though this was a study with a small sample size, and other 
limitations were present, it does suggest that other mechanisms might be responsible for the 
hypoalbuminemia seen in marmosets with CLE. Decreased serum albumin concentrations can also 
be caused by dietary protein deficiency, malassimilation, protein losing nephropathy, and chronic 
hepatopathy. Lesions in the kidney, pancreas, and liver are common concurrent necropsy findings 
in marmosets with CLE.88 Albumin has been reported to be a negative acute phase protein in 
humans,66 rhesus macaques,82 and marmoset.135 It is possible that the hypoalbuminemia seen in 
CLE is a result of chronic systemic inflammation, rather than the presumed enteric protein loss. 
The use of corticosteroids in marmosets with clinical signs of CLE did improve serum albumin 
concentrations.115 Impaired digestive efficiency in marmosets with CLE68 also may contribute to 
the low albumin levels. Larger studies evaluating fecal samples from marmosets with CLE at 
different time points are needed to confirm these results.  
Serum cobalamin and folate concentrations can serve as surrogate markers of 
gastrointestinal disease in dogs and cats where they can have both therapeutic and prognostic 
implications. CLE in the common marmoset, still presents a diagnostic challenge and given the 
frequency that it was observed in captive common marmosets, a diagnostic test is desperately 
needed. Cobalamin and folate concentrations can be measured in serum using an automated 
chemiluminescent immunoassay. The current study  validated a commercially available assay for 
the measurement of serum cobalamin and folate in the common marmoset, established a reference 
interval in healthy marmosets, and then measured serum concentrations of cobalamin and folate 
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in common marmosets with CLE. The commercial assay was linear, accurate, precise, and 
reproducible for the measurement of serum cobalamin and folate in the common marmoset. The 
study also showed that decreased serum folate concentrations were moderately sensitive (>70%) 
for CLE and decreased serum cobalamin concentrations were moderately specific (>70%) for 
CLE. Clinical implications of decreased serum cobalamin and folate concentrations in the common 
marmoset are yet to be determined. 
Measurements of serum cobalamin and folate concentrations may aid in the diagnosis of 
CLE or gastrointestinal disease in general in the marmoset. However marmosets are rather small 
and there are limitations on serum samples that can be collected for evaluation. A naturally voided 
sample of feces or urine used for testing might facilitate easier screening of marmosets for CLE. 
Fecal N-methylhistamine (NMH) concentrations, a breakdown product of histamine released from 
degranulating  mast cells, is increased in dogs with chronic enteropathy.  The role of mast cells 
has not previously been evaluated in marmosets with CLE. Fecal NMH concentrations were 
measured using a gas chromatography–mass spectrometry assay that had previously been 
developed for use with canine fecal extracts. A partial validation was performed. Fecal NMH 
concentrations were measured in 14 marmosets, 7 of 8 marmosets with CLE and one marmoset 
with lymphoma and ulcerative enteritis had increased fecal NMH concentrations. Increased fecal 
NMH concentrations may serve as a potential marker for CLE. However, further studies exploring 
the role of mast cells in CLE in the common marmoset are needed. 
 
8.2 Future directions 
One of the major hypothesis for our study was that hypoalbuminemia seen in marmosets 
with CLE is a result of enteric protein loss. Our study failed to demonstrate increased enteric 
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protein loss, based on normal fecal α1-PI concentrations in marmosets with CLE. Hence, another 
test to see if PLE is a component of CLE in marmosets is indicated. The ‘gold standard test’ in 
other species is the demonstration of fecal clearance of intravenously administered 51Cr or 
99mTechnetium ‐ labeled human serum albumin. Testing this in a small population of terminal 
marmosets with CLE in the future would further help confirm or refute the role of PLE, if any, in 
CLE.  
This study demonstrated abnormal serum concentrations of cobalamin and folate in 
marmosets with CLE, both of which were however only moderately sensitive and specific for the 
detection of CLE or gastrointestinal disease in the common marmoset. It should be noted that the 
diet of the marmosets in this study contained cobalamin. However, the amount of cobalamin 
contained in the diet was unknown. It would be interesting to determine the exact amount of 
cobalamin in the diet fed to marmosets to determine whether this potentially could mask cobalamin 
deficiency due to CLE in some of the animals. Also, serum cobalamin concentrations can be a 
poor marker of cellular cobalamin status, and a follow up test quantifying homocysteine, 
methylmalonic acid, and holo-transcobalamin may prove useful to further evaluate cobalamin 
status in these marmosets. Future studies should explore these cellular markers and this may 
potentially lead to tests with better sensitivity and specificity for the detection of CLE. In some 
human patients methylmalonic acid concentrations increase even before serum cobalamin 
concentration decreases, making it an earlier marker, which would be beneficial in research or 
breeding colonies of marmosets. Urinary concentration of methylmalonic acid can also serve as a 
marker of cobalamin deficiency in humans, and could serve as a non-invasive method of colony 
screening or testing. Hence, there is a significant potential for exploring these markers in future 
studies.  
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Our study showed for the first time that mast cells are present in the gastrointestinal tract 
of marmosets and increased fecal concentrations of N-methylhistamine, a marker of mast cell 
degranulation was increased in a portion of marmosets with CLE. Future studies should evaluate 
a larger number of healthy marmosets and marmosets with CLE, comparing serum, urinary, and 
fecal concentrations of N-methylhistamine to determine if the increase in the fecal concentrations 
is a result of systemic mast cell activation or a local process within the gastrointestinal tract.  
Mast cells have also been shown to release metalloproteinase-9, another marker that has 
been reported previously to be elevated in marmosets with clinical signs comparable with CLE. 
This finding, along with our findings of elevated fecal NMH, does suggest a bigger unexplored 
role for mast cells in CLE. Histamine release is not unique to mast cells, as basophils also carry 
histamine granules. Eosinophil activation can also lead to increased histamine release. As mast 
cells, basophils, and eosinophils express many of the same receptors and cytokines, evaluation of 
specific mast cell markers such as tryptase in feces may be more useful in future studies. Further 
confirmation of mast activity in a larger number of marmosets with CLE by immunohistology 
staining for tryptase or by using transmission electron microscopy looking for evidence of 
degranulation is also warranted. This should be complemented by comparing levels of 
proinflammatory cytokines (e.g., IL-4 and IL-6), other substances synthesized and stored in mast 
cells granules (e.g., β-hexosaminidase activity and serotonin), and transcriptional markers (e.g., 
mRNA levels of MMP9) in gastrointestinal tissue or contents between healthy marmosets and 
marmosets with CLE.  
The confirmation of mast cell activation as a potential driver of marmoset CLE would help 
target the management of affected animals, particularly by advocating the use of mast cells 
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stabilizers, such as oral cromolyn sodium, ketotifen, or natural bioflavonoids, such as quercetin, 
luteolin, or similar pharmaceuticals. 
 
8.3 Conclusions 
In conclusion, common marmosets with CLE do not have increased levels of fecal α1-PI 
concentrations, suggesting that other factors may be contributing to hypoalbuminemia observed in 
these marmosets. In contrast, similar to other species, marmosets with gastrointestinal disease 
show decreased serum concentrations of folate and cobalamin. Also, fecal NMH concentrations 
are increased in marmosets with CLE, suggestive of mast cell involvement in the inflammatory 
process in the gut. Further studies are needed to determine the exact role of mast cells in the 
pathogenesis of CLE in marmosets to help direct therapeutic interventions, to improve treatment 
outcome, and decrease the prevalence of CLE in common marmosets used for biomedical research.  
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